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1. PUBLIC HEALTH STATEMENT
 
This Statement was prepared to give you information about 2,3-benzofuran
and to emphasize the human health effects that may result from exposure to it.
The Environmental Protection Agency (EPA) has identified 1,177 sites on its
National Priorities List (NPL). 2,3-Benzofuran has been found in at least 5
of these sites. However, we do not know how many of the 1,177 NPL sites have
been evaluated for 2,3-benzofuran. As EPA evaluates more sites, the number of 
sites at which 2,3-benzofuran is found may change. This information is
important for you to know because 2,3-benzofuran may cause harmful health
effects and because these sites are potential or actual sources of human
exposure to 2,3-benzofuran. 
When a chemical is released from a large area, such as an industrial
plant, or from a container, such as a drum or bottle, it enters the
environment as a chemical emission. This emission, which is also called a 
release, does not always lead to exposure. You can be exposed to a chemical
only when you come into contact with the chemical. You may be exposed to it
in the environment by breathing, eating, or drinking substances containing the
chemical or from skin contact with it. 
If you are exposed to a hazardous chemical such as 2,3-benzofuran,
several factors will determine whether harmful health effects will occur and 
what the type and severity of those health effects will be. These factors
include the dose (how much), the duration (how long), the route or pathway by
which you are exposed (breathing, eating, drinking, or skin contact), the
other chemicals to which you are exposed, and your individual characteristics
such as age, sex, nutritional status, family traits, life style, and state of
health. 
1.1 WHAT IS 2,3-BENZOFURAN? 
2,3-Benzofuran is a colorless, sweet-smelling, oily liquid which does
not mix with water. 2,3-Benzofuran is made by processing coal into coal oil.
2,3-Benzofuran may also be formed during other uses of coal or oil. The part
of the coal oil that contains 2,3-benzofuran is made into a plastic called
coumarone-indene resin. Coumarone-indene resin can then be used to make 
paint, varnish, glue, and floor tiles, and it is allowed on food products and
packages. We know very little about how 2,3-benzofuran might get into the
environment or what happens to it after it gets there. 
More information on the properties and uses of 2,3-benzofuran and how it
behaves in the environment may be found in Chapters 3, 4, and 5. 
1.2 HOW MIGHT I BE EXPOSED TO 2,3-Benzofuran? 
2,3-Benzofuran has been found in a few places in the air and water. In
most instances, when it was found; the amount that was there was not measured. 
We do not know what the levels of 2,3-benzofuran are in soil, air, water, or 
food. The reason that 2,3-benzofuran has not often been found could be that 
2,3-benzofuran usually attaches to particles, and is not free in the air or
water. We do not know where 2,3-benzofuran comes from, except when it is 
  
   
 
 
2
 
1. PUBLIC HEALTH STATEMENT
 
found near fuel-processing factories. Workers who make coal oil or coumarone­
indene resin might be exposed to 2,3-benzofuran. Cigarette smoke has some
2,3-benzofuran in it. Coumarone-indene resin is allowed in food packages and
as a coating on oranges and grapefruit. .We do not know how often the resin is
used or whether any 2,3-benzofuran in it gets into the food. 
More information on how you might be exposed to 2,3-benzofuran is given
in Chapter 5. 
1.3 HOW CAN 2,3-BENZOFURAN ENTER AND LEAVE MY BODY? 
We know very little about how 2,3-benzofuran can enter or leave your
body. Some 2,3-benzofuran can enter your body from the environment if it is
in the water that you drink, the food that you eat, or the air that you
breathe. We do not know how much you would take in or when and how it would
leave your body. 
More information on how 2,3-benzofuran enters and leaves the body is
given in Chapter 2. 
1.4 HOW CAN 2,3-BENZOFURAN AFFECT MY HEALTH? 
The effect of 2,3-benzofuran on your health depends on how much you take
into your body. In general, the more you take in, the greater the chances
that an effect will occur. No studies have been done to test the effects of 
2,3-benzofuran on the health of humans. Studies in animals show that 
2,3-benzofuran can damage the liver and kidneys if large amounts are given
within a short time, and that very large amounts can kill. We do not know
whether exposure to 2,3-benzofuran can affect your ability to have children or
can harm an unborn baby. 
Studies in animals show that exposure to 2,3-benzofuran at moderate
levels over a long time can damage the liver, kidneys, lungs, and stomach.
The brain, muscles, and heart do not seem to be seriously damaged by long-term
exposure. Some rats and mice that received 2,3-benzofuran for their whole
lives developed cancer of the kidney, lung, liver, or stomach. However, no
cases of cancer in humans have been linked to exposure to 2,3-benzofuran.
More information on the health effects of 2,3-benzofuran in humans and 
animals can be found in Chapter 2. 
1.5 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO 2,3-
BENZOFURAN? 
2,3-Benzofuran can be measured in your blood or in your milk if you are
a nursing mother. The test is specific for 2,3-benzofuran but it requires
special equipment and is not easily available. The test may only be able to
detect 2,3-benzofuran for a certain period of time because it is not known how
long 2,3-benzofuran remains in the body after you have been exposed to it. 
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Also, the test only shows that you have been exposed; it cannot predict which
health effects, if any, you will develop. 
More information on how 2,3-benzofuran can be measured in exposed humans is
given in Chapters 2 and 6. 
1.6 	 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN 
HEALTH? 
No standards have been set for exposure to 2,3-benzofuran. The Food and
Drug Administration specifies the quantity of coumarone-indene resin that may
be used on food and in food packages. 
More information on government regulations for 2,3-benzofuran can be
found in Chapter 7. 
1.7 WHERE CAN I GET MORE INFORMATION? 
If you have any more questions or concerns not covered here, please
contact your state health or environmental department or: 
Agency for Toxic Substances and Disease Registry
Division of Toxicology
1600 Clifton Road, E-29 
Atlanta, Georgia 30333 
This agency can also provide you with information on the location of the
nearest occupational and environmental health clinic. Such clinics specialize
in recognizing, evaluating, and treating illnesses that result from exposure
to hazardous substances. 
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2. HEALTH EFFECTS
 
2.1 INTRODUCTION
 
The primary purpose of this chapter is to provide public health
officials, physicians, toxicologists, and other interested individuals and
groups with an overall perspective of the toxicology of 2,3-benzofuran and a
depiction of significant exposure levels associated with various adverse
health effects. It contains descriptions and evaluations of studies and
presents levels of significant exposure for 2,3-benzofuran based on
toxicological studies and epidemiological investigations. 
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals address the needs of persons living
or working near hazardous waste sites, the information in this section is
organized first by route of exposure--inhalation, oral, and dermal--and then
by health effect--death, systemic, immunological, neurological, developmental,
reproductive, genotoxic, and carcinogenic effects. These data are discussed
in terms of three exposure periods--acute (less than 15 days), intermediate
(15-364 days), and chronic (365 days or more). 
Levels of significant exposure for each route and duration are presented
in tables and illustrated in figures. The points in the figures showing
no-observed-adverse-effect levels (NOAELS) or lowest-observed-adverse-effect
levels (LOAELS) reflect the actual doses (levels of exposure) used in the
studies. LOAELs have been classified into "less serious" or "serious" 
effects. These distinctions are intended to help the users of the document
identify the levels of exposure at which adverse health effects start to
appear. They should also help to determine whether or not the effects vary
with dose and/or duration, and place into perspective the possible
significance of these effects to human health. 
The significance of the exposure levels shown in the tables and figures
may differ depending on the user's perspective. For example, physicians
concerned with the interpretation of clinical findings in exposed persons may
be interested in levels of exposure associated with "serious" effects. Public 
health officials and project managers concerned with appropriate actions to
take at hazardous waste sites may want information on levels of exposure
associated with more subtle effects in humans or animals (LOAEL) or exposure
levels below which no adverse effects (NOAEL) have been observed. Estimates
of levels posing minimal risk to humans (Minimal Risk Levels, MRLs) may be of
interest to health professionals and citizens alike. 
Levels of exposure associated with the carcinogenic effects of
2,3-benzofuran are indicated in Figure 2-l. Cancer effects could occur at
lower exposure levels, but excess risks have not been estimated. 
Estimates of exposure levels posing minimal risk to humans (MRLs) have
been made, where data were believed reliable, for the most sensitive noncancer 
effect for each exposure duration. MRLs include adjustments to reflect human
variability from laboratory animal data to humans. 
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Although methods have been established to derive these levels (Barnes
et al. 1988; EPA 1989), uncertainties are associated with these techniques.
Furthermore, ATSDR acknowledges additional uncertainties inherent in the
application of the procedures to derive less than lifetime MRLs. As an
example, acute inhalation MRLs may not be protective for health effects that
are delayed in development or are acquired following repeated acute insults,
such as hypersensitivity reactions, asthma, or chronic bronchitis. As these
kinds of health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs will be revised. 
2.2.1 Inhalation Exposure 
No studies were located regarding the following health effects in humans
or animals after inhalation exposure to 2,3-benzofuran: 
2.2.1.1 Death 
2.2.1.2 Systemic Effects
2.2.1.3 Immunological Effects
2.2.1.4 Neurological Effects
2.2.1.5 Developmental Effects
2.2.1.6 Reproductive Effects
2.2.1.7 Genotoxic Effects 
No studies were located regarding genotoxic effects in humans or animals
after inhalation exposure to 2,3-benzofuran. Other genotoxicity studies are
discussed in Section 2.4. 
2.2.1.8 Cancer 
No studies were located regarding carcinogenic effects in humans or
animals after inhalation exposure to 2,3-benzofuran. 
2.2.2 Oral Exposure 
No studies were located regarding health effects in humans after oral
exposure to 2,3-benzofuran. 
Most information about the health effects of 2,3-benzofuran comes from 
studies of animals (rats and mice) exposed by gavage, particularly a study by
the National Toxicology Program (NTP 1989). Table 2-l and Figure 2-1 present
a summary of studies that provide reliable quantitative data on the toxicity
of 2,3-benzofuran following oral exposure. The main conclusions from these
studies are discussed below. 
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2.2.2.1 Death 
No studies were located regarding death in humans after oral exposure to
2,3-benzofuran. Oral exposure to 2,3-benzofuran can be lethal to animals.
One female rat given a dose of 500 mg/kg/day died after 4 days, although 4
other female rats and all 5 male rats given this dose survived for 14 days
(NTP 1989). All 10 rats given an oral dose of 1,000 mg/kg/day died within
3 days (NTP 1989). The cause of death was not determined for the rats that
died following acute exposure to 2,3-benzofuran (NTP 1989). Some deaths were
observed among male and female mice in groups orally exposed for 14 days to
doses of 2,3-benzofuran ranging from 31.25 to 250 mg/kg/day (NTP 1989).
However, all mice dying early showed evidence of gavage error (oily fluid in
the pleural cavity), and the pattern of deaths showed no dose-response
relationship (NTP 1989), so that no deaths among mice were attributable to
chemical exposure. 
Some mortality was seen among animals orally exposed to 2,3-benzofuran
for 13 weeks, although the pattern of mortality was somewhat inconsistent.
Among rats, l female out of 10 given 250 mg/kg/day died in week 1, 1 female
out of 10 given 500 mg/kg/day died in week 5, and no male rats died (NTP
1989). The cause of death was not determined for the rats that died following
intermediate-duration exposure to 2,3-benzofuran (NTP 1989). A NOAEL of
125 mg/kg/day and a LOAEL of 250 mg/kg/day is identified for death in rats by
this study. Among mice exposed for 13 weeks, discounting deaths attributable
to gavage error, 1 out of 10 males given 62.5 mg/kg/day died in week 13, no
animals given 125 mg/kg/day died, 1 out of 10 males given 250 mg/kg/day died
in week 12, and 4/7 males and 2/9 females given 500 mg/kg/day died in weeks 1
and 3 (NTP 1989). The cause of death was not determined for the mice that
died following intermediate-duration exposure to 2,3-benzofuran (NTP 1989).
The dose response relationship in this study was inconsistent, but the weight
of evidence is compatible with a NOAEL of 125 mg/kg/day and a LOAEL of
250 mg/kg/day for death in mice. 
Chronic exposure of male rats to 2,3-benzofuran caused a statistically-
significant decrease in survival at doses of 30 and 60 mg/kg/day, attributed
to increased severity of kidney damage (NTP 1989). The survival of female
rats exposed to 60 and 120 mg/kg/day for 103 weeks was not significantly
different from controls (NTP 1989). Female mice exposed to 120 and
240 mg/kg/day had a statistically-significant reduction in survival after
96 weeks, while the survival of male mice exposed to 60 and 120 mg/kg/day for
103 weeks was not different from controls (NTP 1989). When the dose of
2,3-benzofuran was inadvertently increased from 60 to 240 mg/kg/day for male
mice in weeks 20-21, 10 out of 50 animals died (NTP 1989). No cause of death
was reported for those male mice nor was a cause of decreased survival
reported for female mice (NTP 1989). No NOAEL for mortality following
chronic-duration exposure to 2,3-benzofuran is identified by this study. 
The highest NOAEL values and all reliable LOAEL values for death in each
species and duration category are recorded in Table 2-l and plotted in
Figure 2-l. 
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2.2.2.2 Systemic Effects 
No studies were located regarding respiratory, cardiovascular,
gastrointestinal, hematological, musculoskeletal, hepatic, renal, or
dermal/ocular effects in humans after oral exposure to 2,3-benzofuran. 
The systemic effects observed in animals after oral exposure to
2,3-benzofuran are discussed below. The highest NOAEL values and all reliable
LOAEL values for systemic effects in each species and duration category are
recorded in Table 2-l and plotted in Figure 2-1. 
Respiratory Effects. Rats exposed to oral doses of 500 and
1,000 mg/kg/day of 2,3-benzofuran for up to 14 days exhibited a red nasal
discharge, which was not further characterized (NTP 1989). Histological
examinations were performed only on animals in the 250 mg/kg/day dose groups
(NTP 1989). Histological examination of nasal, larynx, trachea, lung, and
bronchial tissues of rats and mice exposed to 2,3-benzofuran by gavage for up
to 2 years showed compound-related hyperplasia in the lungs and nasal mucosa
in chronically-exposed mice (NTP 1989). The lung hyperplasia was seen in all
groups of mice exposed for 103 weeks, in males at doses of 60 and
120 mg/kg/day and in females at doses of 120 and 240 mg/kg/day (NTP 1989).
The hyperplasia occurred in bronchiolar epithelial cells, often extending into
the alveolar ducts (NTP 1989). 
Nasal hyperplasia was observed in both control and chemically-treated
mice in a 103-week study (NTP 1989). The hyperplasia was associated with
inflammation from foreign material (corn oil, hair, and particles of feed and
bedding) lodged in the nasal cavity, and the effect of oral 2,3-benzofuran
exposure was to increase the inflammatory response to such particles,
particularly at the highest dose tested in females, 240 mg/kg/day (NTP 1989). 
Cardiovascular Effects. Histological examination of the heart and
circulatory system of rats and mice exposed to 2,3-benzofuran by gavage for up
to 2 years showed a compound-related increase in mineralization of the
pulmonary artery in chronically-exposed rats (NTP 1989). The NOAEL values for
cardiovascular effects are identified as the highest doses for which
histological examinations were performed (250 mg/kg/day for acute-duration
exposure and 500 mg/kg/day for intermediate-duration exposure).
artery mineralization, Pulmonary nephropathy, which was considered secondary to
increased severity of was seen only in the low-dose groups of rats exposed for
103 weeks (30 mg/kg/day in male rats and 60 mg/kg/day in female rats) (NTP
1989). The lack of effect at the higher doses was attributed to reduced
survival (NTP 1989). 
Gastrointestinal Effects. Histological examination of stomach and
intestines of rats and mice with acute- or intermediate-duration exposure to
2,3-benzofuran by gavage showed no compound-related lesions, but chronic
exposure caused forestomach hyperplasia in rats and mice (NTP 1989). Male
rats exposed for 103 weeks had a significant increase in chronic inflammation
of the forestomach at a dose of 30 mg/kg/day, and significant increases in 
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epithelial hyperplasia and ulcers at a dose of 60 mg/kg/day (NTP 1989). In
mice exposed for 103 weeks, forestomach hyperplasia was increased in males at
the higher dose (120 mg/kg/day) but not at the lower dose (60 mg/kg/day), and
was increased in females in both dose groups (120 and 240 mg/kg/day) (NTP
1989). Only the increase at 120 mg/kg/day in female mice was statistically
significant (NTP 1989). 
Hematological Effects. Histological examination of tissues from the
hematopoietic system of rats and mice exposed to 2,3-benzofuran by gavage for
up to 2 years showed no compound-related lesions at the highest doses examined
(250 mg/kg/day for acute-duration exposure, 500 mg/kg/day for intermediate-
duration 
exposure, and 120 mg/kg/day in rats and 240 mg/kg/day in mice for
chronic-duration exposure) (NTP 1989). Effects of oral exposure to
2,3-benzofuran on hemoglobin, hematocrit, red blood cells, white blood cells,
or other hematological parameters have not been examined in any reported
study. The NOAEL values for hematological effects for each species and
duration category are presented in Table 2-l and Figure 2-l. 
Musculoskeletal Effects. Histological examination of tissues from the
musculoskeletal system of rats and mice exposed to 2,3-benzofuran by gavage
for up to 2 years showed a compound-related increase in bone degeneration
(fibrous osteodystrophy) in chronically-exposed male rats (NTP 1989). The
observed increase in bone degeneration, which was not statistically
significant at doses of either 30 or 60 mg/kg/day, was not considered a direct
effect of 2,3-benzofuran exposure, but as secondary to calcium and phosphate
imbalance due to increased severity of nephropathy in male rats caused by
2,3-benzofuran exposure (NTP 1989). 
Hepatic Effects. The liver is a common target organ for substituted
furan compounds (Boyd 1981). Ten days of oral exposure of female mice to a
dose of 591 mg/kg/day of 2,3-benzofuran altered the activity of several
hepatic enzymes, decreasing the rate of reactions which activate electrophiles
and increasing the rate of reactions which deactivate electrophiles (Cha
et al. 1985; Heine et al. 1986). No toxicity was reported in this study (Cha
et al. 1985; Heine et al. 1986). Liver damage was seen in rats exposed to
2,3-benzofuran by gavage for 13 weeks and in mice exposed for 103 weeks (NTP
1989). Necrosis of individual hepatocytes was observed after 13 weeks of
exposure to 2,3-benzofuran in male rats at doses of 125, 250, and
500 mg/kg/day and in female rats at doses of 250 and 500 mg/kg/day (NTP 1989).
No histology was performed on rats exposed at lower doses so confidence in
125 mg/kg/day as a LOAEL for liver damage is low and no NOAEL can be
established. Cells resembling normal hepatocytes were found adjacent to and
within the pancreatic islets of female rats exposed to 120 mg/kg/day of
2,3-benzofuran for 103 weeks, but these cells were considered to have arisen 
by transdifferentiation of pancreatic cells (NTP 1989). This metaplasia of
the pancreatic islets was not accompanied by any other adverse histologic
changes (NTP 1989). The incidence of multinuclear hepatocytes was increased
in the livers of male mice exposed to 2,3-benzofuran for 103 weeks at doses of
60 and 120 mg/kg/day (NTP 1989); since this effect was seen at the lowest dose
tested, no threshold can be determined. 
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Renal Effects. The kidney appears to be the organ most consistently
affected by 2,3-benzofuran. Male Fisher F344/N rats have a high incidence of
spontaneous nephropathy, characterized by degeneration, necrosis, and
mineralization of tubular cells, and this nephropathy was made more severe by
intermediate- and chronic-duration exposure to 2,3-benzofuran (NTP 1989). The
increased severity of nephropathy was accompanied by additional effects in
chemically-treated rats, including cortical cysts, bone degeneration,
hyperplasia of the parathyroid glands and pelvic epithelium, and
mineralization of the pulmonary artery (NTP 1989). Among male rats exposed
for 13 weeks, increased severity of nephropathy was seen at a dose of
250 mg/kg/day but not at lower doses. Among male rats exposed for 103 weeks,
increased severity of nephropathy contributing to reduced survival was seen at
both doses tested, 30 and 60 mg/kg/day. 
Female rats had a statistically-significant increase in nephropathy
following 13 weeks of exposure to 2,3-benzofuran at doses of 250 and
500 mg/kg/day, but not at 125 mg/kg/day, and exhibited increased severity of
nephropathy following 103 weeks of exposure at both doses tested, 60 and
120 mg/kg/day (NTP 1989). Female rats developed renal tubular cell atypical
hyperplasia following 103 weeks of exposure to a dose of 120 mg/kg/day (NTP
1989). Male mice exhibited kidney lesions (tubular cell necrosis,
inflammation, and focal mineralization) after 13 weeks of 2,3-benzofuran
exposure at a dose of 250 mg/kg/day, but not at lower doses for 13 weeks or at
doses of 60 or 120 mg/kg/day for 2 years (NTP 1989). No kidney damage was
found in female mice at any duration or dose of 2,3-benzofuran, up to
250 mg/kg/day for 14 days, up to 500 mg/kg/day for 13 weeks, or up to
240 mg/kg/day for 2 years (NTP 1989). The highest NOAEL values and all
reliable LOAEL values for renal effects for each species and duration category
are presented in Table 2-l and Figure 2-l. 
Dermal/Ocular Effects. Histological examination of the skin and eyes of
rats and mice exposed to 2,3-benzofuran by gavage for up to 2 years showed no
compound-related lesions at the highest doses examined (250 mg/kg/day for
acute-duration exposure, 500 mg/kg/day for intermediate-duration exposure, and
120 mg/kg/day in rats and 240 mg/kg/day in mice for chronic-duration exposure)
(NTP 1989). Rats exposed to oral doses of 500 and 1,000 mg/kg/day of
2,3-benzofuran for 3-14 days exhibited a red ocular discharge, but this
discharge was not characterized and no histological examinations were
performed on animals in these dose groups (NTP 1989). 
Other Systemic Effects. Oral 2,3-benzofuran exposure resulted in
decreased body weights in some cases (NTP 1989). In rats, reduced body weight
was observed after 14 days of exposure of males at doses of 250 and
500 mg/kg/day and of females at a dose of 500 mg/kg/day, after 13 weeks of
exposure of males at doses of 125, 250, and 500 mg/kg/day and of females at a
dose of 500 mg/kg/day, and after 103 weeks of exposure of males at doses of 30
and 60 mg/kg/day and of females at a dose of 120 mg/kg/day (NTP 1989). In
mice, reduced body weight was observed after 13 weeks of exposure of males at
a dose of 500 mg/kg/day, and after 103 weeks of exposure of males at a dose of
60 mg/kg/day but not 120 mg/kg/day and of females at doses of 120 and 
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240 mg/kg/day (NTP 1989). No explanation was provided for the reduction in
body weight in male mice in the low dose group but not the high dose group
during chronic exposure (NTP 1989). Body weight reduction does not provide
specific information concerning toxicity, and often occurs only at doses above
those causing other systemic effects. The relative sensitivity to body-weight
reduction does appear to parallel the sensitivity to kidney and liver damage:
male rats are most sensitive, followed by female rats, male mice, and female
mice (NTP 1989). 
Rats exposed to 2,3-benzofuran for 13 weeks had an increased incidence
of cytoplasmic vacuolization of the adrenal glands, which was observed in 1
out of 10 control males, 2 out of 10 males at a dose of 250 mg/kg/day, and in
all 20 males and females at a dose of 500 mg/kg/day (NTP 1989). No adrenal
lesions were seen in rats at shorter or longer exposures, and no tests were
made to determine the effect on adrenal functioning. 
In rats exposed to 2,3-benzofuran for 103 weeks, the occurrence of
cystic follicles in the thyroid glands was increased in males at doses of
30 and 60 mg/kg/day but decreased in females at doses of 60 and 120 mg/kg/day
(NTP 1989). Parathyroid hyperplasia was increased in male rats exposed for
103 weeks to a dose of 30 mg/kg/day, secondary to increased severity of
nephropathy (NTP 1989). 
2.2.2.3 Immunological Effects 
No studies were located regarding immunological effects in humans after
oral exposure to 2,3-benzofuran. No abnormalities in lymphatic tissues were
detected by histological examination of rats and mice exposed to
2,3-benzofuran by gavage for up to 2 years (NTP 1989). However, no
examination of lymphocytes or tests of immune system functioning were made, so
these studies do not identify a reliable NOAEL for immunological effects. 
2.2.2.4 Neurological Effects 
No studies were located regarding neurological effects in humans after
oral exposure to 2,3-benzofuran. No abnormalities in the nervous systems were
detected by histopathologic examination of rats and mice exposed to
2,3-benzofuran for up to 2 years (NTP 1989). However, no neurochemical or
neurophysiological parameters were monitored, so these studies do not identify
a reliable NOAEL for neurological effects. 
2.2.2.5 Developmental Effects 
No studies were located regarding developmental effects in humans or
animals after oral exposure to 2,3-benzofuran. 
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2.2.2.6 Reproductive Effects 
No studies were located regarding reproductive effects in humans after
oral exposure to 2,3-benzofuran. No damage to male or female reproductive
organs was detected by histological examination of rats and mice exposed to
2,3-benzofuran by gavage for up to 2 years (NTP 1989). However, no functional
tests of reproductive success have been made, so these studies do not identify
a reliable NOAEL for reproductive effects. 
2.2.2.7 Genotoxic Effects 
No studies were located regarding genotoxic effects in humans or animals
after oral exposure to 2,3-benzofuran. Genotoxicity studies are discussed in
Section 2.4. 
2.2.2.8 Cancer 
No studies were located regarding carcinogenic effects in humans after
oral exposure to 2,3-benzofuran. Chronic gavage exposure to 2,3-benzofuran
increases the frequency of tumors in several organs in rats and mice
(NTP 1989). In rats, a statistically-significant increase in kidney
adenocarcinomas was found in females at a dose of 120 mg/kg/day, but no
carcinogenic effects were seen in males, perhaps because of reduced survival
(NTP 1989). In mice, increased frequencies of tumors were found in lungs,
livers, and forestomachs of both males and females (NTP 1989). Most of these
effects showed a dose-response trend and were statistically significant at
both doses tested, 60 and 120 mg/kg/day in males and 120 and 240 mg/kg/day in
females (NTP 1989). The NTP concluded that the data provided no evidence of
carcinogenicity of 2,3-benzofuran to male rats, some evidence of
carcinogenicity to female rats, and clear evidence of carcinogenicity to male
and female mice (NTP 1989). 
Levels of exposure associated with the observed carcinogenic effects of
2,3-benzofuran are indicated in Figure 2-l. Cancer effects could occur at
lower exposure levels, but no estimate of the individual human lifetime cancer
risks from exposure to 2,3-benzofuran has been made at this time by the EPA. 
2.2.3 Dermal Exposure 
2.2.3.1 Death 
No studies were located regarding death in humans or animals after
dermal exposure to 2,3-benzofuran. 
2.2.3.2 Systemic Effects 
No studies were located regarding respiratory, cardiovascular,
gastrointestinal, hematological, musculoskeletal, hepatic, or renal effects in
humans or animals after dermal exposure to 2,3-benzofuran. 
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Dermal/Ocular Effects. No skin lesions or dermatitis were reported in
an early review of the dermatological problems associated with the manufacture
of coumarone-indene resin (a polymer made from 2,3-benzofuran and indene);
however, the manufacturing process essentially prevented contact with monomers
(Schwartz 1936), so the significance of these negative findings is
questionable. Workers continuously exposed to wood varnished with coumarone­
indene 
resin developed dermatitis, but the sensitivity was attributed to the
sulfuric acids in the varnish (Schwartz 1936). 
No studies were located regarding the following health effects in humans
or animals after dermal exposure to 2,3-benzofuran: 
2.2.3.3 Immunological Effects
2.2.3.4 Neurological Effects
2.2.3.5 Developmental Effects
2.2.3.6 Reproductive Effects
2.2.3.7 Genotoxic Effects 
No studies were located regarding genotoxic effects in humans or animals
after dermal exposure to 2,3-benzofuran. Genotoxicity studies are discussed
in Section 2.4. 
2.2.3.8 Cancer 
No studies were located regarding carcinogenic effects in humans or
animals after dermal exposure to 2,3-benzofuran. 
2.3 TOXICOKINETICS 
2.3.1 Absorption 
2.3.1.1 Inhalation Exposure . 
No studies were located regarding absorption in humans or animals after
inhalation exposure to 2,3-benzofuran. The partitioning of 2,3-benzofuran
between particulate matter and synthetic alveolar surfactant in vitro was
reported to depend upon the chemical nature of the particles (Sehnert and
Risby 1988). Synthetic lung surfactant was able to dissolve 2,3-benzofuran
adsorbed to particles with few active sites, but not 2,3-benzofuran adsorbed
to particles with many active sites (Sehnert and Risby 1988). These data
indicate that inhalation of particles containing 2,3-benzofuran would result
in some absorption, depending on the nature of the particles. 
2.3.1.2 Oral Exposure 
No studies were located regarding absorption in humans or animals after
oral exposure to 2,3-benzofuran. 
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2.3.1.3 Dermal Exposure 
No studies were located regarding absorption in humans or animals after
dermal exposure to 2,3-benzofuran. 
2.3.2 Distribution 
No studies were located regarding distribution in humans or animals
after exposure to 2,3-benzofuran by the following routes: 
2.3.2.1 Inhalation Exposure
2.3.2.2 Oral Exposure
2.3.2.3 Dermal Exposure 
2.3.3 Metabolism 
No studies were located regarding metabolism of 2,3-benzofuran in humans
or animals. However, the metabolism of several other substituted furans has 
been shown to involve oxidation by P-450, with the unsubstituted double bond
of the furan ring converted either to an epoxide (Boyd 1981) or to a
dialdehyde (Ravindranath et al. 1984). Pretreatment with inducers and
inhibitors of P-450 modified the toxicity of a single intraperitoneal
injection of 2,3-benzofuran to male mice (McMurtry and Mitchell 1977). Oral
exposure to 2,3-benzofuran altered the activity of P-450 and other enzymes in
the livers of female mice (Heine et al. 1986). These experiments indicate
that cytochrome P-450 may be involved in the toxicity of 2,3-benzofuran, but
do not provide a clear picture of 2,3-benzofuran metabolism. 
2.3.4 Excretion 
No studies were located regarding excretion in humans or animals after
exposure to 2,3-benzofuran by the following routes: 
2.3.4.1 Inhalation Exposure
2.3.4.2 Oral Exposure
2.3.4.3 Dermal Exposure 
2.4 RELEVANCE TO PUBLIC HEALTH 
As discussed in Section 2.2, estimates of levels of exposure to
2,3-benzofuran posing minimal risk to humans (MRLs) were to have been made,
where data were believed reliable, for the most sensitive noncancer effect for 
each route and exposure duration. However, no MRLs could be derived for
2,3-benzofuran. No data were located on effects of acute-duration, 
intermediate-duration, or chronic-duration inhalation exposure to
2,3-benzofuran in humans or animals. Therefore, no inhalation MRLs were 
derived. Available information on acute-duration oral exposure in animals
does not identify the most sensitive effect or any dose-response relationships
(NTP 1989). Available information on intermediate-duration and chronic duration
oral exposure to 2,3-benzofuran in animals suggests that the most 
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sensitive effect may be liver toxicity following intermediate-duration
exposure and kidney toxicity following chronic-duration exposure (NTP 1989),
but the data do not reliably identify the threshold for liver or kidney
damage. Therefore, no oral MRLs were derived. Acute-duration, intermediate
duration, and chronic-duration dermal MRLs were not derived for 2,3-benzofuran 
due to the lack of an appropriate methodology for the development of dermal
MRLs. 
Essentially nothing is known about the effects of 2,3-benzofuran
exposure on humans. The principal adverse health effects noted in animals
associated with oral exposure to 2,3-benzofuran are kidney and liver damage
(NTP 1989). Intraperitoneal injection of 2,3-benzofuran also causes kidney
and liver damage (McMurtry and Mitchell 1977). Inhalation and dermal
exposures might also produce adverse effects, although this has not been
studied. Because of the limited production and use of 2,3-benzofuran (see
Chapter 4), the average person is unlikely to encounter doses high enough to
cause kidney or liver damage. However, studies in animals indicate that
2,3-benzofuran exposure may increase the risk of cancer (NTP 1989), and so
even low exposure levels may be of concern. Kidney and liver damage, cancer,
and other less common effects are discussed in greater detail below. 
Death. Large oral doses of 2,3-benzofuran can cause death in rats or
mice following acute or intermediate exposure duration, and somewhat lower
chronic doses can reduce survival (NTP 1989). No consistent difference in
sensitivity between male and females has been observed (NTP 1989). The
lethality of 2,3-benzofuran exposure by intraperitoneal injection appears to
be greater than that following gavage exposure, as a single intraperitoneal
injection of 100 mg/kg caused deaths in some male mice (McMurtry and Mitchell
1977), but 14-day gavage exposure caused no deaths in rats or mice at doses up
to 250 mg/kg/day (NTP 1989). The cause of death from 2,3-benzofuran exposure
was not reported in these studies except that reduced survival in male rats
chronically exposed to 2,3-benzofuran was attributed to increased severity of
kidney damage (NTP 1989). An acute dose of 240 mg/kg/day caused death in male
mice in a group which had been exposed to 60 mg/kg/day for 20 weeks, but an
acute dose of 250 mg/kg/day for 14 days caused no deaths in mice which had not
previously been exposed to 2,3-benzofuran (NTP 1989). Although no data were
provided concerning the cause of increased lethality of 2,3-benzofuran
following prior exposure, cumulative organ damage or altered metabolism are
possible explanations. It is unlikely that humans would be exposed to a dose
of 2,3-benzofuran sufficient to cause death. 
Systemic Effects. 
Respiratory Effects. Chronic-duration oral exposure to 2,3-benzofuran
causes hyperplasia of nasal mucosa and lung tissue in mice (NTP 1989).
In vitro exposure of chicken trachea cells to 2,3-benzofuran results in
substantial inhibition of ciliary activity (Pettersson et al. 1982), which may
indicate that ciliotoxicity is involved in the respiratory effects seen in
mice. Certain other furan derivatives exhibit pulmonary toxicity due to
metabolic activation by lung P-450 oxygenases (Boyd 1981), but 2,3-benzofuran 
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has not been studied specifically. No respiratory effects were seen following
acute-, intermediate-, or chronic-duration oral exposure in rats or following
acute- or intermediate-duration oral exposure in mice. Thus, respiratory
effects are seen fairly infrequently, and only at high doses which also cause
liver damage. 
Cardiovascular Effects. Chronic-duration oral exposure to
2,3-benzofuran causes mineralization of the pulmonary artery in rats, but this
effect was due to mineral imbalances and vascular constriction associated with 
kidney damage (NTP 1989). No cardiovascular effects were seen following
acute-, intermediate-, or chronic-duration oral exposure in mice or following
acute- or intermediate-duration oral exposure in rats. 
Gastrointestinal Effects. Chronic-duration oral exposure to
2,3-benzofuran causes chronic inflammation of the forestomach in rats and mice 
(NTP 1989). No gastrointestinal effects were seen following acute- or
intermediate-duration oral exposure in rats or mice. The gastrointestinal
effects were seen at doses causing severe kidney damage or above doses causing
liver damage. 
Musculoskeletal Effects. Chronic-duration oral exposure to
2,3-benzofuran causes bone degeneration in rats, but this effect is due to
mineral imbalances associated with kidney damage (NTP 1989). No
musculoskeletal effects were seen following acute-, intermediate-, or chronic
duration oral exposure in mice or following acute- or intermediate-duration
oral exposure in rats. 
Hepatic Effects. Liver damage is a consistent systemic effect of oral
exposure to 2,3-benzofuran (NTP 1989). Intermediate-duration oral exposure
causes liver damage in male and female rats and chronic-duration oral exposure
causes liver damage in male mice (NTP 1989). Liver damage is also seen
following a single intraperitoneal injection of 2,3-benzofuran (McMurtry and
Mitchell 1977). The observed liver damage is usually characterized by focal
necrosis of hepatocytes after both oral (NTP 1989) and intraperitoneal
(McMurtry and Mitchell 1977) exposure. Liver damage was the systemic effect
seen at the lowest dose in male rats exposed to 2,3-benzofuran for 13 weeks
(NTP 1989). 
The toxicity of 2,3-benzofuran to the liver may be associated with
activation by P-450 oxygenases. Pretreatment of mice with an inhibitor of
P-450 oxygenases, cobaltous chloride, prevents liver damage from
intraperitoneal injection of 2,3-benzofuran (McMurtry and Mitchell 1977).
Acute-duration oral exposure to 2,3-benzofuran alters the activity of hepatic
enzymes in mice, decreasing the cytochrome P-450 content and increasing the
activity of several enzymes involved in the deactivation of electrophiles (Cha
et al. 1985; Heine et al. 1986). This overall shift in metabolism away from
activation of potential carcinogens was taken to suggest that 2,3-benzofuran
might have anticarcinogenic activity (Cha et al. 1985; Heine et al. 1986). 
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However, because chronic-duration exposure to 2,3-benzofuran increases the
incidence of cancer in rodents, including liver cancer in mice (NTP 1989), any
possible anticarcinogenic action of 2,3-benzofuran is less relevant. 
Renal Effects. Intermediate- and chronic-duration oral exposure to
2,3-benzofuran causes kidney damage in male and female rats and intermediate-
duration oral exposure causes kidney damage in male mice (NTP 1989).
Intraperitoneal injection also causes kidney damage in male mice (McMurtry and
Mitchell 1977). Kidney damage involves injury to the tubular cells, with
degeneration, necrosis, and mineralization. In male rats (a group predisposed
to kidney damage), chronic 2,3-benzofuran exposure increases the severity of
the nephropathy to an extent which affects survival at a lifetime dose of
30 mg/kg/day (NTP 1989). Kidney damage seen in rats following chronic-duration
oral exposure to 2,3-benzofuran also involved cortical cysts, bone
degeneration, hyperplasia of the parathyroid glands and pelvic epithelium, and
mineralization of the pulmonary artery (NTP 1989). 
Other Systemic Effects. Oral exposure to 2,3-benzofuran causes
decreased body weight in rats and mice, and damage to adrenal and thyroid
glands in rats (NTP 1989). Reduced body weight is a rather unspecific
indicator of toxicity, and was generally not seen except at doses also causing
liver or kidney damage. Adrenal and thyroid lesions were seen infrequently,
and there was no indication of an effect on organ function (NTP 1989). 
The systemic effects caused by 2,3-benzofuran exposure which are most
relevant to public health are liver and kidney damage. Other systemic
effects, including damage to the adrenal and thyroid glands, lungs, and
pancreas, and reduced body weight, are generally seen only at doses above
those causing kidney or liver damage. High-level exposure to 2,3-benzofuran
would be expected to damage the liver or kidney, and possibly other organs in
some individuals. 
Immunological Effects. Oral lifetime exposure to 2,3-benzofuran caused
no histopathological lesions in lymphatic tissues of rats or mice (NTP 1989).
This provides limited evidence that the immunological system may not be a
major target for 2,3-benzofuran toxicity, but more definitive conclusions are
not possible without further studies. 
Neurological Effects.  Oral lifetime exposure to 2,3-benzofuran caused
no histopathological lesions in tissues of the nervous systems of rats or mice
(NTP 1989). However, no tests of neurological function were performed, and so
the significance of these negative findings with regard to public health
cannot be evaluated. 
Developmental Effects.  No information is available concerning any
effects on development from 2,3-benzofuran exposure. 
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Reproductive Effects.  Oral lifetime exposure to 2,3-benzofuran caused
no histopathological lesions in male or female reproductive organs of rats or
mice (NTP 1989). However, no studies of organ function or reproductive
success have been made, and so the potential effects of 2,3-benzofuran
exposure on human reproduction cannot be evaluated. 
Genotoxic Effects.  No in vivo studies of 2,3-benzofuran genotoxicity
were located. The genotoxicity of 2,3-benzofuran has been studied in a number
of in vitro systems (Table 2-2). 2,3-Benzofuran was found not to be mutagenic
to Salmonella tvphimurium, both with and without exogenous activation (Florin
et al. 1980; Haworth et al. 1983; Weill-Thevenet et al. 1981). However
2,3-benzofuran does give positive responses in genotoxicity assays for
mutagenicity to mouse lymphoma L5178Y cells (McGregor et al. 1988) and for
sister chromatid exchanges in Chinese hamster ovary cells (NTP 1989). Limited
evidence suggests that 2,3-benzofuran could be metabolized to an electrophilic
epoxide or dialdehyde (see Section 2.3.3), and such an intermediate would be
an alkylating agent capable of reacting with DNA. Thus, one possible
explanation for the mixed genotoxicity results is differences among the
metabolic conditions used in the various tests. 
Cancer.  2,3-Benzofuran is carcinogenic to rats and mice (NTP 1989).
Chronic oral exposure increased the incidence of kidney tumors in female rats,
and increased the incidence of lung, forestomach, and liver tumors in male and
female mice (NTP 1989). These findings indicate that chronic exposure to
2,3-benzofuran could be a cause of concern even at low levels; however, 
without more extensive exposure data, it is not possible to characterize the
magnitude of human cancer risk from 2,3-benzofuran exposure. 
No information is available concerning the mechanism of carcinogenicity
of 2,3-benzofuran. All of the tissues showing a carcinogenic response also
exhibited hyperplasia, but there was no evidence that neoplasia was a
progression from hyperplasia (NTP 1989). Substituted furans can be activated
by cytochrome P-450 to electrophilic intermediates (epoxides or dialdehydes)
(Boyd 1981; Ravindranath et al. 1984), and furan and furfural can activate
oncogenes in mouse liver (NTP 1989; Reynolds et al. 1987); however, the
metabolism of 2,3-benzofuran has not been specifically studied. A possible
mechanism for the carcinogenicity of 2,3-benzofuran is electrophilic attack on
DNA. The evidence that 2,3-benzofuran has only limited genotoxicity in vitro
(see Table 2-2) could be the result of inadequate metabolic activation. 
2.5 BIOMARRERS OF EXPOSURE AND EFFECT 
Biomarkers are broadly defined as indicators signaling events in
biologic systems or samples. They have been classified as markers of
exposure, markers of effect, and markers of susceptibility (NAS/NRC 1989). 
A biomarker of exposure is a xenobiotic substance or its metabolite(s)
or the product of an interaction between a xenobiotic agent and some target
molecule(s) or cell(s) that is measured within a compartment of an organism
(NAS/NRC 1989). The preferred biomarkers of exposure are generally the 
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substance itself or substance-specific metabolites in readily obtainable body
fluid(s) or excreta. However, several factors can confound the use and
interpretation of biomarkers of exposure. The body burden of a substance may
be the result of exposures from more than one source. The substance being
measured may be a metabolite of another xenobiotic substance (e.g., high
urinary levels of phenol can result from exposure to several different
aromatic compounds). Depending on the properties of the substance (e.g.,
biologic half-life) and environmental conditions (e.g., duration and route of
exposure), the substance and all of its metabolites may have left the body by
the time biologic samples can be taken. It may be difficult to identify
individuals exposed to hazardous substances that are commonly found in body
tissues and fluids (e.g., essential mineral nutrients such as copper, zinc,
and selenium). Biomarkers of exposure to 2,3-benzofuran are discussed in
Section 2.5.1. 
Biomarkers of effect are defined as any measurable biochemical,
physiologic, or other alteration within an organism that, depending on
magnitude, can be recognized as an established or potential health impairment
or disease (NAS/NRC 1989). This definition encompasses biochemical or
cellular signals of tissue dysfunction (e.g., increased liver enzyme activity
or pathologic changes in female genital epithelial cells), as well physiologic
signs of dysfunction such as increased blood pressure or decreased lung
capacity. Note that these markers are often not substance specific. They
also may not be directly adverse, but can indicate potential health impairment
(e.g., DNA adducts). Biomarkers of effects caused by 2,3-benzofuran are
discussed in Section 2.5.2. 
A biomarker of susceptibility is an indicator of an inherent or acquired
limitation of an organism's ability to respond to the challenge of exposure to
a specific xenobiotic substance. It can be an intrinsic genetic or other
characteristic or a preexisting disease that results in an increase in
absorbed dose, biologically effective dose, or target tissue response. If
biomarkers of susceptibility exist, they are discussed in Section 2.7,
"POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE." 
2.5.1 Biomarkers Used to Identify and/or Quantify Exposure to 2,3-Benzofuran 
2,3-Benzofuran has been detected in samples of breast milk (Pellizzari
et al. 1982) and in blood from victims who died in fires (Anderson and Harland
1980), but no information was provided by either study on previous exposure to
2,3-benzofuran. No information was located concerning metabolites of
2,3-benzofuran in animals or humans. No information was located concerning
the fate of 2,3-benzofuran in animals or humans, so it is not possible to
predict how long 2,3-benzofuran remains in the body, or how body levels might
correlate with exposure or effects. 
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2.5.2 Biomarkers Used to Characterize Effects Caused by 2,3-Benzofuran 
No information is available concerning the effects of 2,3-benzofuran in
humans. Acute oral exposure to 2,3-benzofuran has been shown to alter levels
of enzyme activity in the livers of female mice (Heine et al. 1986), but much
more work would need to be done to determine whether there is a pattern of
enzyme alteration specific to 2,3-benzofuran exposure. Other effects found in
animals following oral exposure to 2,3-benzofuran are kidney and liver damage
and kidney, lung, liver, and stomach cancer (see Section 2.2.2). Such
generalized responses do not suggest the basis for any specific biomarker of
clinical or preclinical effects caused by 2,3-benzofuran. 
2.6 INTERACTIONS WITH OTHER CHEMICALS 
Pretreatment of male mice with compounds that affect cytochrome P-450
oxygenases altered the toxicity of a single intraperitoneal injection of
2,3-benzofuran (McMurtry and Mitchell 1977). However, kidney necrosis was
decreased both by phenobarbital, which induces P-450, and by cobaltous
chloride and piperonyl butoxide, which inhibit P-450. Also, one of the P-450
inhibitors, cobaltous chloride, decreased lethality while the other, piperonyl
butoxide, increased lethality. Differential effects on liver and kidney P-450
systems could explain some of these observations. Compounds which affect
P-450 metabolism are likely to alter 2,3-benzofuran toxicity, but the effects
on P-450 are not predictive of the specific effects on 2,3-benzofuran
toxicity. 
2.7 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
Studies of 2,3-benzofuran toxicity in animals reveal differences in
susceptibility between sexes and between species, with male rats being the
most sensitive (see Section 2.2). Male rats have a high rate of spontaneous
kidney disease, and their greater sensitivity to 2,3-benzofuran toxicity may
be because the target organ is already damaged. Although no studies provide
data concerning human susceptibility, it is reasonable to assume that persons
with kidney or liver disease would be more susceptible to the toxic effects of
2,3-benzofuran. In addition, people who have altered P-450 metabolism, due to
disease, alcoholism, age, or exposure to drugs or chemicals, would be expected
to have altered 2,3-benzofuran toxicity (see Section 2.3.3), but the extent or
the direction of the effect (protective or harmful) cannot be predicted. 
2.8 MITIGATION OF EFFECTS 
This section will describe clinical practice and research concerning methods
for reducing toxic effects of exposure to 2,3-benzofuran. However, because
some of the treatment discussed may be experimental and unproven, this section
should not be used as a guide for treatment of exposures to 2,3-benzofuran.
When specific exposures have occurred, poison control centers and medical
toxicologists should be consulted for medical advice. 
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Human exposure to 2,3-benzofuran can occur by inhalation, ingestion, or by
dermal contact. Also, 2,3-benzofuran has been detected in human milk and can 
thus be transferred to a nursing infant (Pellizzari et al. 1982). Essentially
nothing is known about the effects of 2,3-benzofuran exposure on humans. No
information was located on treatment for 2,3-benzofuran specifically, but the
sources listed below provided information for the general class of "phenols“
and indicated that this information applied to 2,3-benzofuran exposure;
however, it is not known if all of this information applies to 2,3-benzofuran
exposure. General recommendations for reducing adsorption following acute
exposure have included removal of the chemical with undiluted polyethylene
glycol prior to washing with large quantities of water (HSDB 1992). If the
eyes have been exposed, irrigation with copious amounts of tepid water has
been suggested (HSDB 1992). If ingestion has occurred, gastric lavage may be
indicated if performed soon after ingestion, or in patients who are comatose
or at risk of convulsing (HSDB 1992). Administration of activated charcoal
slurry, aqueous or mixed with saline cathartic or sorbitol has also been
suggested (HSDB 1992). Diazepam may be helpful in controlling seizures (HSDB
1992). 
Very little data is available on the retention of 2,3-benzofuran. Synthetic
lung surfactant was able to dissolve 2,3-benzofuran adsorbed to some particles
(Sehnert and Risby 1988), suggesting that it may be absorbed through the
lungs. Some substituted furans have been shown to be metabolized by the P-450
enzyme system (Boyd 1981; Ravindranath et al. 1984), suggesting that this is a
likely metabolic route for 2,3-benzofuran as well. Certain drugs, such as
cobaltous chloride and piperonyl butoxide, inhibit this enzyme system, and
were shown to alter the liver and kidney toxicity of 2,3-benzofuran (McMurtry
and Mitchell 1977). However, not all treatments with inhibitors and inducers
of the P-450 system gave the expected results in this study. One possible
explanation for these discrepancies could be the differential effects on the
different P-450 systems. It is possible that one or more drugs with this
activity could be developed and used to inhibit metabolism of 2,3-benzofuran
to more toxic metabolites. 
Little is known about the effects of 2,3-benzofuran exposure on humans. The
principal adverse health effects noted in animals associated with oral
exposure to 2,3-benzofuran are kidney and liver damage (NTP 1989). In the
kidney, 2,3-benzofuran causes injury to the tubular cells, with degeneration,
necrosis, and mineralization. In the liver, damage due to 2,3-benzofuran is
usually characterized by focal necrosis of hepatocytes. However, the
mechanism(s) associated with this damage are unknown. A better understanding
of the mechanism of action of 2,3-benzofuran may make it possible to develop
effective methods to reduce toxic effects caused by exposure. 
2.9 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of
ATSDR (in consulXation with the Administrator of EPA and agencies and programs
of the Public Health Service) to assess whether adequate information on the
health effects of 2,3-benzofuran is available. Where adequate information is 
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not available, ATSDR, in conjunction with the National Toxicology Program
(NTP), is required to assure the initiation of a program of research designed
to determine the health effects (and techniques for developing methods to
determine such health effects) of 2,3-benzofuran. 
The following categories of possible data needs have been identified by
a joint team of scientists from ATSDR, NTP, and EPA. They are defined as
substance-specific informational needs that, if met, would reduce or eliminate
the uncertainties of human health assessment. In the future, the identified 
data needs will be evaluated and prioritized, and a substance-specific
research agenda will be proposed. 
2.9.1 Existing Information on Health Effects of 2,3-Benzofuran 
The existing data on health effects of inhalation, oral, and dermal
exposure of humans and animals to 2,3-benzofuran are summarized in Figure 2-2.
The purpose of this figure is to illustrate the existing information
concerning the health effects of 2,3-benzofuran. Each dot in the figure
indicates that one or more studies provide information associated with that
particular effect. The dot does not imply anything about the quality of the
study or studies. Gaps in this figure should not be interpreted as "data
needs" information (i.e., data gaps that must necessarily be filled). 
No data exist on the health effects of 2,3-benzofuran in humans. No 
data exist on the health effects of 2,3-benzofuran in animals following
inhalation or dermal exposure. Information on the health effects in rats and
mice following oral exposure to 2,3-benzofuran comes primarily from a well-
conducted gavage study by NTP of acute-, intermediate-, and chronic-duration
(NTP 1989). However, this NTP study was limited to examining
histopathological endpoints, so information on immunologic, neurologic and
reproductive effects does not include evidence concerning organ or system
function. In addition, developmental and in vivo genotoxic effects of
2,3-benzofuran exposure have not been studied. 
2.9.2 Data Needs 
Acute-Duration Exposure. No data are available on the effects of acute-
duration exposure to 2,3-benzofuran in humans. No data are available on the
effects of 2,3-benzofuran in animals following inhalation and dermal exposure.
Lethality in rats was reported in the NTP gavage study but the cause of death
was not known. The only systemic effects observed were red ocular and nasal
discharges and decreased body weights (NTP 1989). Lethality as well as kidney
and liver damage were seen in mice following a single intraperitoneal
injection of 2,3-benzofuran (McMurtry and Mitchell 1977). Currently, little
or no information is available concerning the target organ or the dose-
response of toxicity following inhalation, oral, or dermal exposure, and no
oral or inhalation MRLs could be derived. Toxicokinetic data for acute-
duration exposure are insufficient to identify targets or to allow conclusions
to be made across routes of exposure. Such data are unlikely to become
available from human studies, but establishing the end points and levels 
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causing toxicity from acute exposure of animals to 2,3-benzofuran by all three
routes would be useful to evaluate risk to populations surrounding hazardous
waste sites who might be exposed to 2,3-benzofuran for brief periods. 
Intermediate-Duration Exposure.  No data are available on the effects of 
intermediate-duration exposure to 2,3-benzofuran in humans. No information is
available on the effects of 2,3-benzofuran in animals following inhalation or
dermal exposure of intermediate duration, and no inhalation MRL could be
derived. Histological evidence of liver damage in male rats exposed to
2,3-benzofuran by gavage for 13 weeks was reported in the lowest dose group
examined (125 mg/kg/day) (NTP 1989). Thus, no threshold for liver damage was
established by these studies and no oral MRL could be calculated. No renal
effects were observed in rats or mice at the dose causing necrosis of liver
cells in male rats, but kidney damage was observed at the next higher dose
tested, 250 mg/kg/day, in rats and mice (NTP 1989). Studies to establish an
oral MRL would be helpful in evaluating risk to populations near hazardous
waste sites who might be exposed to 2,3-benzofuran for intermediate durations.
Such studies would be valuable if they included examination of liver and
kidney function in addition to histopathology. Toxicokinetic data for
intermediate-duration exposure are insufficient to identify targets or to
allow conclusions to be made across routes of exposure. As for acute-duration
exposure, human data are unlikely to become available, but go-day animal
studies using several doses and investigating a number of end points would be
helpful for assessing the levels which may cause health effects in humans
following inhalation or dermal exposure to 2,3-benzofuran. 
Chronic-Duration Exposure and Cancer.  No data are available on the 
effects of chronic-duration exposure to 2,3-benzofuran in humans. The NTP
study of oral exposure established the kidney as the most sensitive target
organ in rats (NTP 1989), but no oral MRL could be derived because the kidney
damage in male rats at the lowest dose used, 30 mg/kg/day, was too severe to
establish a threshold. Studies using lower doses would establish a LOAEL for
less serious effects and a NOAEL, which could also be better defined by tests
of kidney function as well as histopathology. Currently, no information is
available concerning the target organ or the dose-response of toxicity
following inhalation or dermal exposure, and no inhalation MRL could be
derived. Toxicokinetic data are insufficient to identify targets or to allow
conclusions to be made across routes of exposure. Such information would be
useful to evaluate risks to population near hazardous waste sites who might be
exposed to 2,3-benzofuran for long periods of time. As for acute- and
intermediate-duration exposure, human data are unlikely to become available,
but animal studies would help define levels expected to cause adverse health
effects in humans chronically exposed to 2,3-benzofuran by oral, inhalation,
and dermal routes. 
No epidemiologic studies were located concerning the potential human
carcinogenicity of 2,3-benzofuran. Lifetime oral exposure increases cancer
incidence in female rats and in male and female mice (NTP 1989). The
carcinogenicity in both sexes and both species, as well as in multiple organs,
strengthens the likelihood of a carcinogenic potential in humans. Studies of 
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the carcinogenicity of 2,3-benzofuran by inhalation or dermal exposure would
be useful if toxicokinetic studies were to show substantial route-specific
differences in absorption, distribution, metabolism, or excretion. 
Genotoxicity.  No data are available on the genotoxicity of
2,3-benzofuran in humans or animals. Genotoxicity results in vitro are mixed,
with negative results in the most widely used genotoxicity test,
S. tvphimurium mutagenicity (Florin et al. 1980; Haworth et al. 1983; McGregor
et al. 1988; NTP 1989; Weill-Thevenet et al. 1981). Other substituted furans
appear to be activated by P-450 oxygenases to epoxide (Boyd 1981) or
dialdehyde (Ravindranath et al. 1984) intermediates, which are electrophilic
and hence likely to react with DNA; however, the metabolism of 2,3-benzofuran
has not been studied. The mixed genotoxicity in vitro could reflect
inadequate activation, and so additional studies of in vivo metabolism and
genotoxicity in animals (e.g., 32P post-labeling to detect DNA adducts
following exposure to 2,3-benzofuran) would be useful to confirm or refute the
genotoxic potential of 2,3-benzofuran. 
Reproductive Toxicity.  No data are available on the reproductive
toxicity of 2,3-benzofuran in humans. No histopathologic lesions were
reported in male or female reproductive organs in rats or mice following
acute-, intermediate-, or chronic-duration oral exposure to 2,3-benzofuran
(NTP 1989). However, no tests of organ function or reproductive success were
done. Thus, limited data indicate that the reproductive system may not be a
major target for 2,3-benzofuran toxicity, but further studies in animals by
all three routes of exposure examining reproductive organ pathology and organ
functions would be useful for assessing the possible effects of 2,3-benzofuran
exposure on human reproduction. 
Developmental Toxicity.  No data are available on the developmental
toxicity of 2,3-benzofuran in humans or animals. Thus, a complete
investigation of the effects of 2,3-benzofuran on development, studying one
rodent and one nonrodent species exposed by all three routes, would be useful
to evaluate potential developmental toxicity in humans. 
Immunotoxicity.  No data are available on the immunotoxicity of
2,3-benzofuran in humans. No histopathologic abnormalities in lymphatic
tissues of rats or mice were found following acute-, intermediate-, or
chronic-duration oral exposure to 2,3-benzofuran (NTP 1989), indicating that
the immune system may not be a target for 2,3-benzofuran toxicity. However, a
battery of immune function tests has not been performed. A more thorough
investigation could begin by examining peripheral lymphocytes in exposed
animals, followed by more detailed studies if effects were found. 
Neurotoxicity.  No data are available on the neurotoxicity of
2,3-benzofuran in humans. No histopathologic lesions were noted in the
nervous systems of rats or mice following acute-, intermediate-, or chronic-
duration oral exposure to 2,3-benzofuran (NTP 1989), but no neurochemical or
neurophysiological parameters were monitored. It would be helpful to conduct 
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neurological tests on animals exposed to 2,3-benzofuran by all three routes to
establish if the nervous system may be a target for 2,3-benzofuran toxicity. 
Epidemiological and Human Dosimetry Studies.  No epidemiological or
human dosimetry studies on the effects of 2,3-benzofuran were located.
Production of coumarone-indene resin involves potential exposure to
2,3-benzofuran (Powers 1980), and so an occupationally exposed subpopulation
could be identified. Animal studies suggest that kidney and liver damage and
increased risk of cancer would be end points of concern (NTP 1989). Potential
difficulties with epidemiological investigations include a small cohort of
exposed workers, the difficulty of defining exposure levels, and the
possibility that exposure to other chemicals could confound the results.
Information from epidemiological and human dosimetry studies would be useful
in establishing cause/effect relationships and in planning future monitoring
of individuals living near hazardous waste sites. 
Biomarkers of Exposure and Effect.  The presence of 2,3-benzofuran has
been detected in breast milk (Pellizzari et al. 1982) and in blood from
victims who died in fires (Anderson and Harland 1980), indicating that the
concentration of 2,3-benzofuran in biological samples could serve as a
biomarker of exposure. However, more studies on absorption, distribution,
metabolism, and excretion would be useful to determine the lifetime of 
2,3-benzofuran in the body and to correlate levels with duration and degree of
exposure. Indirect evidence suggests that 2,3-benzofuran may be activated by
P-450 oxygenases to an epoxide or dialdehyde intermediate which could react
with cellular components (Heine et al. 1986; McMurtry and Mitchell 1977).
Thus, an assay for adducts of 2,3-benzofuran in proteins or DNA could possibly
be developed as a useful marker of exposure to 2,3-benzofuran. 
The effects of 2,3-benzofuran exposure in humans are not known.
Activities of enzymes in the liver are altered by acute exposure to
2,3-benzofuran in female mice (Heine et al. 1986), which suggests the
possibility that there may be a specific response of serum enzyme levels to
2,3-benzofuran exposure that could be developed as a biomarker of effect.
Other effects in animals include kidney and liver damage and an increased rate
of kidney, lung, liver, and forestomach cancer (NTP 1989). Such effects are
too general and severe to serve as biomarkers of 2,3-benzofuran effects. 
Absorption, Distribution, Metabolism, and Excretion.  No data are 
available on the absorption, distribution, metabolism, or excretion of
2,3-benzofuran in humans. Limited data suggest the involvement of P-450
oxygenases in the metabolism of 2,3-benzofuran in animals (Heine et al. 1986;
McMurtry and Mitchell 1977), and further investigations would be valuable to
define the role of organ-specific oxygenases in the toxicity and potential
genotoxicity of 2,3-benzofuran. Absorption, distribution, and excretion in
animals have not been studied at all via inhalation, oral, or dermal routes. 
Such information would be valuable because the relative rates and extent of 
absorption, distribution, metabolism, and excretion following exposure by
different routes may account for differences in the toxicity of a chemical
administered by different routes. These investigations could start with 
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monitoring levels as a function of exposure, by the inhalation, oral, and
dermal routes, and at acute, intermediate, and chronic durations. It is 
likely that 2,3-benzofuran exists in the environment primarily adsorbed to
particles (see Chapter 5), and the extent of desorption of 2,3-benzofuran by
artificial lung surfactant in vitro depends on the nature of the particles
(Sehnert and Risby 1988). Thus, studies of absorption would be most useful if
they included exposure to 2,3-benzofuran on particles representative of those
found in the environment. 
Comparative Toxicokinetics.  No data are available on toxicokinetics in 
animals or humans. There is some commonality of target organs (the kidney and
liver) between rats and mice (NTP 1989), making it reasonable to assume that
both species, and perhaps humans, would handle 2,3-benzofuran similarly.
Establishing which animal species serves as the best model for extrapolating
results to humans would be a useful first step in investigating comparative
toxicokinetics. 
Mitigation of Effects.  No information was located concerning mitigation
of effects of exposure to 2,3-benzofuran. Information on techniques to
mitigate low-level, long-term effects would be useful in determining the
safety and effectiveness of possible methods for treating 2,3-benzofuran exposed
populations in the vicinity of hazardous waste sites. 
2.9.3 On-going Studies 
No information concerning research projects in progress to investigate
2,3-benzofuran was located. 

 37 
3. CHEMICAL AND PHYSICAL INFORMATION 
3.1  CHEMICAL IDENTITY 
Table 3-l lists common synonyms, trade names, and other pertinent
identification information for 2,3-benzofuran. 
3.2 PHYSICAL AND CHEMICAL PROPERTIES
 Table 3-2 lists important physical and chemical properties of
2,3-benzofuran. 
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4. PRODUCTION, IMPORT, USE, AND DISPOSAL 
4.1 PRODUCTION 
2,3-Benzofuran is produced as a component of the crude heavy solvent
fraction of the coal-tar light oil formed by the coking of bituminous coal
(HSDB 1989; Windholz et al. 1983). 2,3-Benzofuran is not isolated for
commercial purposes (HSDB 1989). The fraction of this coal-tar oil distilling
at 167-184°C contains small quantities (probably less than 10%) (Powers 1980)
of 2,3-benzofuran (also known as coumarone) and also indene (approximately
30%) (NTP 1989), indan, substituted benzenes, and related compounds (CFR
1989a). This fraction of coal oil is used to produce a polymer called
coumarone-indene resin (Powers 1980). The polymerization is accomplished by
addition of an acid catalyst such as boron trifluoride (NTP 1989) or sulfuric
acid (HSDB 1989). Coumarone-indene resin hardens when heated and is used to
make floor tiles and other products (HSDB 1989; Morris 1953; NTP 1989).
Coumarone-indene resin is produced by the Neville Chemical Company of Neville
Island, Pennsylvania (SRI 1989). 
No quantitative data were located regarding the production of
2,3-benzofuran or coumarone-indene resin, although it is reported that
virtually all of the resin-forming fraction produced by destructive
distillation of coal is polymerized (Powers 1980). No information was located
concerning the stability or decomposition products of coumarone-indene resin. 
4.2 IMPORT/EXPORT 
Imports of 2,3-benzofuran in 1977 and 1979 have been reported to be
1,840 metric tons and 0.0009 metric tons, respectively (HSDB 1989). Current
information regarding 2,3-benzofuran import was not located. 
No data were located regarding the export of 2,3-benzofuran. 
4.3 USE 
2,3-Benzofuran is not isolated for commercial purposes, and no
information was located regarding uses of isolated 2,3-benzofuran. However,
the coumarone-indene resin may be used as a coating on grapefruit, lemons,
limes, oranges, tangelos, and tangerines (CFR 1989a). Coumarone-indene resin
is also used in the production of paints and varnishes for corrosion-resistant
coatings (Morris 1953; NTP 1989) and water-resistant coatings on paper
products and fabrics (NTP 1989) and as adhesives in food containers (CFR
1989d). Coumarone-indene resin has been used in asphalt floor tiles (Morris
1953; Wilson and McCormick 1960). 
No data were located which would indicate the extent to which 
2,3-benzofuran or coumarone-indene resin is currently used in these products. 
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4.4 DISPOSAL 
2,3-Benzofuran is not listed as a hazardous waste by the EPA. No data
were located regarding rules or regulations which control the disposal of
2,3-benzofuran. 
No data were located regarding disposal methods or disposed quantities
of waste 2,3-benzofuran. 
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5.1 OVERVIEW 
2,3-Benzofuran is a colorless organic liquid with an aromatic odor. It
is produced by the destructive distillation of coal, and may also be formed
during processing of fossil fuels, such as coke production and coal
gasification. Limited data indicate that 2,3-benzofuran may partition to
soils and sediments from water, but the information available is insufficient 
to predict the environmental fate of this compound. Substantial
bioconcentration in aquatic organisms is not expected based on the
physical/chemical properties of 2,3-benzofuran. 
Monitoring data on 2,3-benzofuran in environmental media are scarce.
Potential human exposure to 2,3-benzofuran may occur by ingestion of foods
treated with coumarone-indene resin; however, migration of 2,3-benzofuran from
this resin has not been confirmed. Occupational exposure to 2,3-benzofuran
may occur in several energy-related industries, and individuals living in the
vicinity of hazardous waste sites at which this compound has been detected may
also be exposed. The EPA has identified 1,177 NPL sites. 2,3-Benzofuran has
been found at 5 of the sites evaluated for the presence of this chemical (View
1989). However, it is not known how many of the 1,177 NPL sites have been
evaluated for 2,3-benzofuran. As more sites are evaluated by the EPA, the
number may change. The frequency of the sites in the United States at which
2,3-benzofuran was found can be seen in Figure 5-l. 
5.2 RELEASES TO THE ENVIRONMENT 
2,3-Benzofuran may be released to the environment from production and
use of 2,3-benzofuran-containing products, and from coke production, coal
gasification, and oil-shale facilities. 2,3-Benzofuran is not listed on the
SARA Section 313 Toxics Release Inventory (TRI). 
5.2.1 Air 
Data on 2,3-benzofuran air emissions are sparse. No information was
located regarding 2,3-benzofuran releases from production facilities.
However, 2,3-benzofuran was detected in emissions from a Swedish floor finish 
used on domestic flooring (van Netten et al. 1988), and in emissions from the
pyrolysis of silk (Junk and Ford 1980), and in combustor flue gas emissions
from fluidized-bed coal combustion at a concentration of 900 ng/g (Hunt et al.
1982). Exhaust produced by an automobile burning simple hydrocarbon fuels
contained 2,3-benzofuran at concentrations ranging from less than 0.1 to
2.8 ppm (Seizinger and Dimitriades 1972), but an analysis of air in a highway
tunnel in use by both diesel- and gasoline-powered vehicles indicated no
2,3-benzofuran (Hampton et al. 1982). 
5.2.2 Water 
2,3-Benzofuran may be released to water from coal gasification
facilities. 2,3-Benzofuran was detected in coal gasification facility
effluents at concentrations ranging from 6 to 267 ppb, but was not detected 
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(detection limit 0.1 ppb) in effluents from oil shale processing facilities
(Pellizzari et al. 1979). 2,3-Benzofuran was also detected in 1 of 18 waste
water concentrates (Lucas 1984). Data from the Contract Laboratory Program
(CLP) Statistical Database indicate that 2,3-benzofuran was found at a
concentration of 770 ppb in a groundwater sample, but was not found in any
surface water samples, taken at one hazardous waste site (CLPSD 1990). It is
not known how many hazardous waste sites have been evaluated for
2,3-benzofuran. Note that these data from the CLP Statistical Database 
represent frequency of occurrence and concentration information for NPL sites
only. 
5.2.3 Soil 
2,3-Benzofuran was found at a concentration of 60 ppb in one
soil/sediment sample taken at one hazardous waste site (CLPSD 1990). It is
not known how many hazardous waste sites have been evaluated for
2,3-benzofuran. Note that these data from the CLP Statistical Database 
represent frequency of occurrence and concentration information for NPL sites
only. 
5.3 ENVIRONMENTAL FATE 
5.3.1 Transport and Partitioning 
No information was located on the transport and partitioning of
2,3-benzofuran in the atmosphere. Based on the high boiling point of
2,3-benzofuran, volatilization would be expected to be slow, but because the
vapor pressure of the chemical is unknown, it is not possible to predict how
2,3-benzofuran will partition in the atmosphere. 
2,3-Benzofuran is reported not to be soluble in water (Windholz et al.
1983). However, based on its octanol/water partition coefficient (Table 3-2),
the solubility of 2,3-benzofuran may be on the order of 200 mg/L, using the
empirical regressions of Hassett et al. (1983) for hydrophobic organic
chemicals. 
2,3-Benzofuran may partition from water to soils and sediments. The
extent of adsorption of neutral organic compounds by soils is often correlated
with the organic-carbon content of the soil (Hassett et al. 1983). When
adsorption is expressed as a function of organic-carbon content, an organic
carbon/water partition coefficient (Koc) is generated, and may be used to
classify the relative mobility of the chemical in soil. Based on its
octanol/water partition coefficient, an estimated Koc for 2,3-benzofuran is 
about 330, using the empirical regression of Hassett et al. (1983). This Koc 
implies that 2,3-benzofuran has a medium mobility in soil, using the mobility
classifications of Roy and Griffin (1985), and would be most mobile in soils
and groundwater where the organic-carbon content is low. No soil adsorption
studies on 2,3-benzofuran were located. A coal-tar/water partition
coefficient of 912 for 2,3-benzofuran was derived that was similar in 
magnitude to the octanol/water partition coefficient (Rostad et al. 1985). 
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Lignite coal is able to adsorb 2,3-benzofuran from aqueous solution (Humenick
et al. 1982), which indirectly confirms the expectation that the mobility of
the chemical will be influenced by the distribution of organic carbon. 
The potential for 2,3-benzofuran to be bioconcentrated by aquatic
organisms is likely to be moderate. A bioconcentration factor (BCF) is the
ratio of the concentration of a chemical in the tissues of aquatic animals to
the concentration of the chemical in the water in which they live. No
experimentally measured value for the BCF of 2,3-benzofuran was located, but
the octanol-water partition coefficient (KOW) of 2,3-benzofuran has been
measured as 468 (Leo et al. 1971). The empirical regressions of Neeley et al.
(1974) relate the values of KOW, and BCF for other compounds, and can be used
to estimate that the BCF of 2,3-benzofuran is approximately 40. If this
estimate is correct, substantial bioconcentration of 2,3-benzofuran by aquatic
organisms would not be expected. 
5.3.2 Transformation and Degradation 
5.3.2.1 Air 
No information was located on the transformation or degradation of
2,3-benzofuran in the atmosphere. 
5.3.2.2 Water 
No information was located on the transformation or degradation of
2,3-benzofuran in water. 
5.3.2.3 Soil 
No information was located on the transformation or degradation of
2,3-benzofuran in soils, sediments, or waste water treatment processes. 
5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT 
5.4.1 Air 
2,3-Benzofuran was detected, but not quantitated, in 1 of 10 samples of
ambient air taken in an industrial area in the Kanawha Valley, West Virginia
(Erickson and Pellizzari 1978). No other monitoring data for 2,3-benzofuran
in the United States were located. However, one study identified
2,3-benzofuran among pollutants in the air of the Southern Black Forest in
Germany (Juttner 1986). 
5.4.2 Water 
No information was located regarding 2,3-benzofuran in surface water in
the United States. 2,3-Benzofuran was detected in contaminated groundwater at
a coal-tar distillation and wood-preserving facility in Minnesota (Rostad
et al. 1985). 
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5.4.3 Soil 
No studies were located regarding occurrence of 2,3-benzofuran in soils.
2,3-Benzofuran was among those chemicals selected as representative compounds
of waste chemicals from energy production for, subsurface transport research
(Zachara et al. 1984). 
5.4.4 Other Environmental Media 
2,3-Benzofuran has not generally been reported in foods. However,
2,3-benzofuran was detected among the volatile constituents of freeze-dried
whey powder subjected to accelerated browning (Ferretti and Flanagan 1971).
It was also detected in three samples of human milk (Pellizzari et al. 1982)
and is reportedly a constituent of cigarette smoke (Curvall et al. 1984;
Florin et al. 1980; Schlotzhauer and Chortyk 1987). 
Although 2,3-benzofuran is a component of coumarone-indene resin and
this resin has been approved by the FDA for use as a coating on citrus fruits,
as a component of food-preparation utensils, and as an adhesive in food
packages (see Table 7-l), no information was located confirming that
coumarone-indene resin is currently used on food in the United States.
Furthermore, no data were located to indicate that 2,3-benzofuran migrates
from the resin into foodstuffs. 
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE 
Humans may be exposed to 2,3-benzofuran by inhalation, ingestion, or
dermal absorption. Based on the limited data available, exposure of the
general population to 2,3-benzofuran does not appear to be substantial.
However, since this compound has been detected at hazardous waste sites, is
reported to be a component of cigarette smoke, and is one monomer in a resin
which may be used as a coating on citrus fruits and in packaging materials for
foods, human exposure may be possible from these sources. People in Britain
who had died in fires had 2,3-benzofuran in some blood samples, but no source
of exposure was identified (Anderson and Harland 1980). 2,3-Benzofuran was
detected in human milk (Pellizzari et al. 1982); this indicates possible
exposure of the mother and is an exposure source for the infant. 
Occupational exposure to 2,3-benzofuran may occur in several energy-
related industries. 2,3-Benzofuran is part of the naphtha fraction of coal
distillates and exposure is possible in coke production and coal gasification
facilities (see Chapter 4). Exposure may also occur during the polymerization
process used to produce coumarone-indene resin. 2,3-Benzofuran was not
included in the NIOSH National Occupational Hazard Survey or the National
Occupational Exposure Survey. However, the naphtha fraction of coal tar is
considered in the NIOSH (1978) evaluation of occupational hazards associated
with coal gasification. 
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5.6 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
Individuals occupationally exposed to coal tars or the naphtha fraction
of coal-tar distillate have potentially high exposure to 2,3-benzofuran.
Persons living near industrial sources or hazardous waste sites contaminated
with 2,3-benzofuran may be exposed to 2,3-benzofuran. There are insufficient
data to identify any other populations with potentially high exposure to this
compound. 
5.7 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of
ATSDR (in consultation with the Administrator of EPA and agencies and programs
of the Public Health Service) to assess whether adequate information on the
health effects of 2,3-benzofuran is available. Where adequate information is
not available, ATSDR, in conjunction with the NTP, is required to assure the
initiation of a program of research designed to determine the health effects
(and techniques for developing methods to determine such health effects) of
2,3-benzofuran. 
The following categories of possible data needs have been identified by
a joint team of scientists from ATSDR, NTP, and EPA. They are defined as
substance-specific informational needs that, if met, would reduce or eliminate
the uncertainties of human health assessment. In the future, the identified 
data needs will be evaluated and prioritized, and a substance-specific
research agenda will be proposed. 
5.7.1 Data Needs 
Physical and Chemical Properties.  Measured values of the physical and
chemical properties of 2,3-benzofuran necessary to predict the environmental
fate and transport of this chemical are not available. Reliable measurements
of the vapor pressure, solubility in water, Henry's law constant, and Koc 
would be useful for more accurate prediction of the behavior of 2,3-benzofuran
in environmental media. 
Production, Import/Export, Use, and Disposal.  No recent quantitative
data were located on the production, import/export, use, or disposal of
2,3-benzofuran. Virtually all of the 2,3-benzofuran produced by the
destructive distillation of coal is reportedly used in the production of
coumarone-indene resin (Powers 1980), but no information was located detailing
the current uses of this resin, the composition of this resin, the amount of
2,3-benzofuran emitted from the resin, or the current production volume of the
resin. 2,3-Benzofuran is not listed as a hazardous waste by the EPA;
therefore, no regulations restricting land disposal apply to this chemical.
Data required to assess potential human exposure to this chemical include the
amount of production and import/export of 2,3-benzofuran and coumarone-indene
resin, and emission rates of 2,3-benzofuran from the resin. If the data 
indicate that 2,3-benzofuran is emitted from the resin, then current 
information on the nature and extent of use of the resin will also be 
49
 
5. POTENTIAL FOR HUMAN EXPOSURE
 
necessary. Data on environmental releases of 2,3-benzofuran from production
facilities and disposal methods employed for wastes containing this chemical
would also be helpful to assess potential human exposure. 
Environmental Fate.  The available data on partitioning, transport, and
transformation are insufficient to predict the environmental fate of
2,3-benzofuran. Measurements of the rate of photodegradation of
2,3-benzofuran in the atmosphere and determination of the composition and fate
of the decay products would be useful to predict the atmospheric fate of this
compound. Information regarding the potential for 2,3-benzofuran to
photodegrade or oxidize in water or to biodegrade in water or soil, and the
rates at which these reactions occur, would be useful in predicting the fate
of the compound in these media. Physical/chemical properties suggest that
2,3-benzofuran can partition to soils (Hassett et al. 1983; Roy and Griffin
1985). Verification of this prediction by measurements of the adsorption and
desorption of 2,3-benzofuran by soils and sediments, and measurement of the
rate of volatilization of the compound from water, would be useful in
predicting the transport and partitioning of 2,3-benzofuran among
environmental media. 
Bioavailability from Environmental Media.  The available data are 
insufficient to assess the bioavailability of 2,3-benzofuran from
environmental media. In vitro evidence suggests that 2,3-benzofuran would be
less available from organic-rich particles than from organic-poor particles
(Sehnert and Risby 1988), but confirmation of this prediction with in vivo
studies would be useful. Animal studies have used gavage in oil for exposure
to 2,3-benzofuran (NTP 1989) but no quantitative information concerning
absorption is available. Additional information on the bioavailability of
2,3-benzofuran would be useful to assess the extent of absorption of
2,3-benzofuran from environmental media. 
Food Chain Bioaccumulation.  No data were located regarding the
bioconcentration of 2,3-benzofuran in plants, aquatic organisms, or animals.
Based on physical/chemical properties, substantial bioconcentration of
2,3-benzofuran is not expected (Leo et al. 1971; Neeley et al. 1974). No data
on biomagnification in terrestrial or aquatic food chains are available. Data
on bioconcentration of this compound in aquatic species would be useful in
confirming the predicted low bioconcentration potential of this compound. 
Exposure Levels in Environmental Media. Monitoring data for
2,3-benzofuran are sparse and are insufficient to assess the potential for
human exposure to this compound, so no estimates of human intake of this
substance are available. Since 2,3-benzofuran is a coal-tar product (Powers
1980), monitoring data for this compound in all environmental media in the
vicinity of fossil fuel facilities would help to determine the potential for
both general population and occupational exposure. In addition, monitoring
foods which come in contact with coumarone-indene resin for 2,3-benzofuran 
would be useful to assess the potential for human exposure from food. 
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Remedial investigations and feasibility studies at hazardous waste sites are
potential sources of information on possible exposures of populations
surrounding hazardous waste sites. 
Exposure Levels in Humans.  2,3-Benzofuran has been detected in several 
samples of breast milk (Pellizzari et al. 1982). It is unknown whether the
presence of this compound in milk is a result of exposure to 2,3-benzofuran
itself, or whether it is a metabolite of other compounds. Biological
monitoring of workers in coal gasification or related facilities and of
c populations surrounding hazardous waste sites would be useful to evaluate
human exposure to this compound. 
Exposure Registries.  No exposure registries for 2,3-benzofuran were
located. This compound is not currently one of the compounds for which a
subregistry has been established in the National Exposure Registry. The
compound will be considered in the future when chemical selection is made for
subregistries to be established. The information that is amassed in the
National Exposure Registry facilitates the epidemiological research needed to
assess adverse health outcomes that may be related to the exposure to this
compound. 
5.7.2 On-going Studies 
No information was located on any on-going studies on the fate,
transport, or potential for human exposure to 2,3-benzofuran. Remedial
investigations and feasibility studies at hazardous waste sites may provide
information on environmental levels, transport, and transformation of
2,3-benzofuran. 
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The purpose of this chapter is to describe the analytical methods that
are available for detecting and/or measuring and monitoring 2,3-benzofuran in
environmental media and in biological samples. The intent is not to provide
an exhaustive list of analytical methods that could be used to detect and
quantify 2,3-benzofuran. Rather, the intention is to identify well-established
methods that are used as the standard methods of analysis. No
methods approved by federal agencies or other groups specifically for
detection of 2,3-benzofuran were located. 
Environmental media or biological samples which contain 2,3-benzofuran
are also likely to contain numerous other organic compounds with similar
chemical and physical properties. Analysis of such samples generally proceeds
by first extracting or concentrating some subset of the organic compounds and
then separating and identifying them. Techniques for extraction of organic
compounds from environmental media or biological samples include absorption
onto a polymer and extraction with an organic solvent. Recovery is generally
not complete, and so accurate quantification requires using matrix spikes (EPA
1986c). This has not been done in any studies for 2,3-benzofuran. Sensitive
and selective techniques for identification of organic compounds in extracts
are well established, using high-resolution gas chromatography (HRGC) to
separate the compounds and mass spectrometry (MS) to identify them. HRGC
achieves higher resolution than standard gas chromatography (GC) by using
wall-coated capillary columns rather than packed columns for separation of
compounds. Flame ionization detection is not specific enough for the analysis
of 2,3-benzofuran in samples containing numerous other compounds, although it
has been used to monitor the stability of 2,3-benzofuran in oil for animal
feeding studies (NTP 1989). Accurate quantification of the concentration of
chemicals in extracts can be achieved with GC/MS by daily calibration using
actual and surrogate standards (EPA 1986c), although this has not been done
specifically for 2,3-benzofuran. 
6.1 BIOLOGICAL MATERIALS 
2,3-Benzofuran has been detected, but not quantified, in samples of
blood (Anderson and Harland 1980) and breast milk (Pellizzari et al. 1982).
In both cases, volatile and semi-volatile organic compounds were purged from
the biological fluids by bubbling with an inert gas at an elevated
temperature. The compounds were trapped by adsorption onto a Tenax®
cartridge. The percent recovery of 2,3-benzofuran by this purge-and-trap
collection method was not examined. The Tenax® cartridge was heated to desorb
the organic compounds directly into the inlet of the HRGC equipment. Mass
spectrometry was used to identify the compounds, including 2,3-benzofuran, by
mass fragmentation patterns. The percent recovery or concentration was not
quantified in either study (Anderson and Harland 1980; Pellizzari et al.
1982). 
Methods for detection of 2,3-benzofuran in biological.materials are
summarized in Table 6-1. 
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6.2 ENVIRONMENTAL SAMPLES 
2,3-Benzofuran can be trapped and concentrated from air samples by
passing a large volume of air through a Tenax® (Erikson and Pellizzari 1978;
Juttner 1986; van Netten et al. 1988) or Chromosorb (Seizinger and Dimitriades
1972) cartridge. The cartridge is then thermally desorbed into an HRGC/MS
detection system similar to that used for biological samples. 2,3-Benzofuran
can be concentrated from water samples using the purge-and-trap method
(Pellizzari et al. 1979), or extraction with dichloromethane (Rostad et al.
1985), and analyzed by HRGC/MS. 2,3-Benzofuran can be extracted from
particulate samples with dichloromethane and analyzed by HRGC/MS (Ferretti and
Flanagan 1971; Hunt et al. 1982). The percent recovery of 2,3-benzofuran by
these extraction methods has not been analyzed. The amount of 2,3-benzofuran
in some environmental samples has been quantified (Pellizzari et al. 1979;
Seizinger and Dimitriades 1972), but the precision of the quantification was
not examined. 
Methods for the determination of 2,3-benzofuran in environmental samples
are summarized in Table 6-2. 
6.3 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of
ATSDR (in consultation with the Administrator of EPA and agencies and programs
of the Public Health Service) to assess whether adequate information on the
health effects of 2,3-benzofuran is available. Where adequate information is
not available, ATSDR, in conjunction with the NTP, is required to assure the
initiation of a program of research designed to determine the health effects
(and techniques for developing methods to determine such health effects) of
2,3-benzofuran. 
The following categories of possible data needs have been identified by
a joint team of scientists from ATSDR, NTP, and EPA. They are defined as
substance-specific informational needs that, if met, would reduce or eliminate
the uncertainties of human health assessment. In the future, the identified 
data needs will be evaluated and prioritized, and a substance-specific
research agenda will be proposed. 
6.3.1 Data Needs 
Methods for Determining Biomarkers of Exposure and Effect. The only
known biomarker of exposure to 2,3-benzofuran is its presence in blood
(Anderson and Harland 1980) or breast milk (Pellizzari et al. 1982).
2,3-Benzofuran was not found in all samples of blood or. breast milk tested,
but since existing methods for detection of 2,3-benzofuran in biological
samples are not quantitative, it is not possible to assess whether those
samples contained no 2,3-benzofuran or whether the method used was not
sufficiently sensitive to measure background levels in the population. The
levels at which human health effects occur are not known. Only the
administered doses, not the target organ concentrations, are known for 

  
 
55
 
6. ANALYTICAL METHODS
 
biological effects occurring in animals (NTP 1989), but these doses are
relatively high (30 mg/kg/day or greater, see Chapter 2). Based on the
general sensitivity of HRGC/MS methods, it is likely that levels of
2,3-benzofuran at which biological effects occur should be achievable with
routine quantification procedures. The overall techniques of extraction
followed by HRGC/MS analysis can be made precise, accurate, reliable, and
specific, so that the opportunity exists to develop methods for sensitive
quantitation of 2,3-benzofuran in biological samples. Refinement of existing
purge-and-trap extraction techniques and investigation of alternative
concentration techniques such as cryotrapping (Pankow and Rosen 1988) and
supercritical fluid extraction (King 1989) would be useful. High-performance
liquid chromatography as an alternative to HRGC and Fourier transform infrared
spectroscopy and photodiode array detectors as alternatives to MS detection
might offer advantages. Investigation of possible metabolites of
2,3-benzofuran as biomarkers of exposure would be most useful if accompanied
by development of methods for their detection, such as immunoassay techniques
and 32P post-labelling for identifying macromolecular adducts. 
No known biomarkers of effect were located in the literature. 
Investigation of biomarkers of effect of 2,3-benzofuran would be most useful
if it were also to focus on developing precise, accurate, reliable, and
specific methods for measuring background levels of the biomarker of effect in
the population and also levels at which adverse effects occur. 
Methods for Determining Parent Compounds and Degradation Products in
Environmental Media.  The purpose of the analytical methods for 2,3-benzofuran
is to identify contaminated areas and to determine if contaminant levels
constitute a concern for human health. The media of most concern for human 
exposure to 2,3-benzofuran are drinking water, soil, and air. It is likely
that 2,3-benzofuran exists in these media primarily adsorbed to organic-rich
particulates (Hassett et al. 1983). 2,3-Benzofuran has been found relatively
infrequently in environmental media, but most samples have excluded
particulates. Insufficient work has been done on quantification of
2,3-benzofuran, particularly percent recovery, to determine whether the
methods are sensitive enough to measure background levels in the environment
(Erikson and Pellizzari 1978; Hunt et al. 1982; Juttner 1986; Pellizzari
et al. 1979; Rostad et al. 1985; Seizinger and Dimitriades 1972). The levels
of 2,3-benzofuran at which health effects occur in animals are equivalent to
400 ppm in the diet or more (NTP 1989). Existing methods have nominal
detection limits of 0.1 ppb (Pellizzari et al. 1979; Seizinger and Dimitriades
1972), indicating that existing methods are probably sensitive enough to
detect levels at which health effects occur. The basic techniques of HRGC/MS
have the potential for excellent precision, accuracy, reliability, and
specificity, with sufficient research and development. One novel technique
which may be suitable for in situ monitoring of 2,3-benzofuran in water is
surface-enhanced Raman spectroscopy using silver electrodes (Carrabba et al.
1987). No information is available concerning degradation products of
2,3-benzofuran; investigation of 2,3-benzofuran degradation would be most
useful if it included development of reliable analytical methods. 
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6.3.2 On-going Studies 
No information was located concerning studies directed towards improving
methods for detection of 2,3-benzofuran specifically. 
57 
7. REGULATIONS AND ADVISORIES 
No regulations or advisories that apply specifically to 2,3-benzofuran
were located. 2,3-Benzofuran is one component of coumarone-indene resin and a
number of regulations and guidelines have been established for coumaron-eindene
resin by various national agencies. These values are summarized in
Table 7-l. 
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9. GLOSSARY
 
Acute Exposure -- Exposure to a chemical for a duration of 14 days or less, as
specified in the Toxicological Profiles. 
Adsorption Coefficient (Koc) -- The ratio of the amount of a chemical adsorbed 
per unit weight of organic carbon in the soil or sediment to the concentration
of the chemical in solution at equilibrium. 
Adsorption Ratio (Kd) -- The amount of a chemical adsorbed by a sediment or
soil (i.e., the solid phase) divided by the amount of chemical in the solution
phase, which is in equilibrium with the solid phase, at a fixed solid/solution
ratio. It is generally expressed in micrograms of chemical sorbed per gram of
soil or sediment. 
Bioconcentration Factor (BCF) -- The quotient of the concentration of a
chemical in aquatic organisms at a specific time or during a discrete time
period of exposure divided by the concentration in the surrounding water at
the same time or during the same period. 
Cancer Effect Level (CEL) -- The lowest dose of chemical in a study, or group
of studies, that produces significant increases in the incidence of cancer (or
tumors) between the exposed population and its appropriate control. 
Carcinogen -- A chemical capable of inducing cancer. 
Ceiling Value -- A concentration of a substance that should not be exceeded, 
even instantaneously. 
Chronic Exposure -- Exposure to a chemical for 365 days or more, as specified
in the Toxicological Profiles. 
Developmental Toxicity -- The occurrence of adverse effects on the developing
organism that may result from exposure to a chemical prior to conception
(either parent), during prenatal development, or postnatally to the time of
sexual maturation. Adverse developmental effects may be detected at any point
in the life span of the organism. 
Embryotoxicity and Fetotoxicity -- Any toxic effect on the conceptus as a
result of prenatal exposure to a chemical; the distinguishing feature between
the two terms is the stage of development during which the insult occurred.
The terms, as used here, include malformations and variations, altered growth,
and in utero death. 
EPA Health Advisory -- An estimate of acceptable drinking water levels for a
chemical substance based on health effects information. A health advisory is
not a legally enforceable federal standard, but serves- as technical guidance
to assist federal, state, and local officials. 
Immediately Dangerous to Life or Health (IDLH) -- The maximum environmental 
concentration of a contaminant from which one could escape within 30 min
without any escape-impairing symptoms or irreversible health effects. 
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Intermediate Exposure -- Exposure to a chemical for a duration of 15-364 days
as specified in the Toxicological Profiles. 
Immunologic Toxicity -- The occurrence of adverse effects on the immune system
that may result from exposure to environmental agents such as chemicals. 
In Vitro -- Isolated from the living organism and artificially maintained, as
in a test tube. 
In Vivo -- Occurring within the living organism. 
Lethal Concentration(Lo) (LCLo) -- The lowest concentration of a chemical in 
air which has been reported to have caused death in humans or animals. 
Lethal Concentration(50) (LC50)  -- A calculated concentration of a chemical in 
air to which exposure for a specific length of time is expected to cause death
in 50% of a defined experimental animal population. 
Lethal Dose(Lo) (LDLo) -- The lowest dose of a chemical introduced by a route
other than inhalation that is expected to have caused death in humans or
animals. 
Lethal Dose(50) (LD50) -- The dose of a chemical which has been calculated to 
cause death in 50% of a defined experimental animal population. 
Lethal Time(50) (LT50) -- A calculated period of time within which a specific
concentration of a chemical is expected to cause death in 50% of a defined
experimental animal population. 
Lowest-Observed-Adverse-Effect Level (LOAEL) -- The lowest dose of chemical in 
a study or group of studies, that produces statistically or biologically
significant increases in frequency or severity of adverse effects between the
exposed population and its appropriate control. 
Malformations -- Permanent structural changes that may adversely affect
survival, development, or function. 
Minimal Risk Level -- An estimate of daily human exposure to a chemical that
is likely to be without an appreciable risk of deleterious effects
(noncancerous) over a specified duration of exposure. 
Mutagen -- A substance that causes mutations. A mutation is a change in the
genetic material in a body cell. Mutations can lead to birth defects,
miscarriages, or cancer. 
Neurotoxicity -- The occurrence of adverse effects on the nervous system
following exposure to chemical. 
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No-Observed-Adverse-Effect Level (NOAEL) -- The dose of chemical at which 
there were no statistically or biologically significant increases in frequency
or severity of adverse effects seen between the exposed population and its
appropriate control. Effects may be produced at this dose, but they are not
considered to be adverse. 
Octanol-Water Partition Coefficient (KOW) -- The equilibrium ratio of the
concentrations of a chemical in n-octanol and water, in dilute solution. 
Permissible Exposure Limit (PEL) -- An allowable exposure level in workplace
air averaged over an 8-hour shift. 
q1*-- The upper-bound estimate of the low-dose slope of the dose-response
curve as determined by the multistage procedure. The ql* can be used to 
calculate an estimate of carcinogenic potency, the incremental excess cancer
risk per unit of exposure (usually µg/L for water, mg/kg/day for food, and
µg/m3 for air). 
Reference Dose (RfD) -- An estimate (with uncertainty spanning perhaps an
order of magnitude) of the daily exposure of the human population to a
potential hazard that is likely to be without risk of deleterious effects
during a lifetime. The RfD is operationally derived from the NOAEL (from
animal and human studies) by a consistent application of uncertainty factors
that reflect various types of data used to estimate RfDs and an additional
modifying factor, which is based on a professional judgment of the entire
database on the chemical. The RfDs are not applicable to nonthreshold effects
such as cancer. 
Reportable Quantity (RQ) -- The quantity of a hazardous substance that is
considered reportable under CERCLA. Reportable quantities are: (1) 1 lb or
greater or (2) for selected substances, an amount established by regulation
either under CERCLA or under Sect. 311 of the Clean Water Act. Quantities are 
measured over a 24-hour period. 
Reproductive Toxicity -- The occurrence of adverse effects on the reproductive
system that may result from exposure to a chemical. The toxicity may be
directed to the reproductive organs and/or the related endocrine system. The
manifestation of such toxicity may be noted as alterations in sexual behavior,
fertility, pregnancy outcomes, or modifications in other functions that are
dependent on the integrity of this system. 
Short-Term Exposure Limit (STEL) -- The maximum concentration to which workers 
can be exposed for up to 15 min continually. No more than four excursions are
allowed per day, and there must be at least 60 min between exposure periods.
The daily TLV-TWA may not be exceeded. 
Target Organ Toxicity -- This term covers a broad range of adverse effects on
target organs or physiological systems (e.g., renal, cardiovascular) extending
from those arising through a single limited exposure to those assumed over a
lifetime of exposure to a chemical. 
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Teratogen -- A chemical that causes structural defects that affect the 
development of an organism. 
Threshold Limit Value (TLV) -- A concentration of a substance to which most 
workers can be exposed without adverse effect. The TLV may be expressed as a
TWA, as a STEL, or as a CL. 
Time-weighted Average (TWA) -- An allowable exposure concentration averaged
over a normal 8-hour workday or 40-hour workweek. 
Toxic Dose (TD50) -- A calculated dose of a chemical, introduced by a route
other than inhalation, which is expected to cause a specific toxic effect in
50% of a defined experimental animal population. 
Uncertainty Factor (UF) -- A factor used in operationally deriving the RfD
from experimental data. UFs are intended to account for (1) the variation in
sensitivity among the members of the human population, (2) the uncertainty in
extrapolating animal data to the case of human, (3) the uncertainty in
extrapolating from data obtained in a study that is of less than lifetime
exposure, and (4) the uncertainty in using LOAEL data rather than NOAEL data.
Usually each of these factors is set equal to 10. 
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USER'S GUIDE 
Chapter 1 
Public Health Statement 
This chapter of the profile is a health effects summary written in nontechnical
language. Its intended audience is the general public especially people living
in the vicinity of a hazardous waste site or substance release. If the Public
Health Statement were removed from the rest of the document, it would still 
communicate to the lay public essential information about the substance. 
The major headings in the Public Health Statement are useful to find specific
topics of concern. The topics are written in a question and answer format. The
answer to each question includes a sentence that will direct the reader to
chapters in the profile that will provide more information on the given topic. 
Chapter 2 
Tables and Figures for Levels of Significant Exposure (LSE) 
Tables (2-1, 2-2, and 2-3) and figures (2-l and 2-2) are used to summarize health
effects by duration of exposure and endpoint and to illustrate graphically levels
of exposure associated with those effects. All entries in these tables and
figures represent studies that provide reliable, quantitative estimates of
No-Observed-Adverse-Effect Levels (NOAELs), Lowest-Observed- Adverse-Effect
Levels (LOAELs) for Less Serious and Serious health effects, or Cancer Effect
Levels (CELs). In addition, these tables and figures illustrate differences in
response by species, Minimal Risk Levels (MRLs) to humans for noncancer end
points, and EPA's estimated range associated with an upper-bound individual
lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. The LSE tables and 
figures can be used for a quick review of the health effects and to locate data
for a specific exposure scenario. The LSE tables and figures should always be
used in conjunction with the text. 
The legends presented below demonstrate the application of these tables and
figures. A representative example of LSE Table 2-l and Figure 2-l are shown.
The numbers in the left column of the legends correspond to the numbers in the
example table and figure. 
LEGEND 
See LSE Table 2-l 
(1). Route of Exposure  One of the first considerations when reviewing the
toxicity of a substance using these tables and figures should be the
relevant and appropriate route of exposure. When sufficient data exist, 
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three LSE tables and two LSE figures are presented in the document. The
three LSE tables present data on the three principal routes of exposure,
i.e., inhalation, oral, and dermal (LSE Table 2-1, 2-2, and 2-3,
respectively). LSE figures are limited to the inhalation (LSE Figure 2-l)
and oral (LSE Figure 2-2) routes. 
(2). Exposure Duration  Three exposure periods: acute (14 days or less);
intermediate (15 to 364 days); and chronic (365 days or more) are
presented within each route of exposure. In this example, an inhalation
study of intermediate duration exposure is reported. 
(3).	 Health Effect The major categories of health effects included in
LSE tables and figures are death, systemic, immunological,
neurological, developmental, reproductive, and cancer. NOAELs and
LOAELs can be reported in the tables and figures for all effects but
cancer. Systemic effects are further defined in the "System" column
of the LSE table. 
(4). Key to Figure  Each key number in the LSE table links study information
to one or more data points using the same key number in the corresponding
LSE figure. In this example, the study represented by key number 18 has
been used to define a NOAEL and a Less Serious LOAEL (also see the two
"18r" data points in Figure 2-l). 
(5). Species  The test species, whether animal or human, are identified in this
column. 
(6). Exposure Frequency/Duration  The duration of the study and the weekly and
daily exposure regimen are provided in this column. This permits
comparison of NOAELs and LOAELs from different studies. In this case (key
number 18), rats were exposed to [substance x] via inhalation for 13
weeks, 5 days per week, for 6 hours per day. 
(7). System  This column further defines the systemic effects. These systems
include: respiratory, cardiovascular, gastrointestinal, hematological,
musculoskeletal, hepatic, renal, and dermal/ocular. "Other" refers to any
systemic effect (e.g., a decrease in body weight) not covered in these
systems. In the example of key number 18, one systemic effect
(respiratory) was investigated in this study. 
(8).	 NOAEL A No-Observed-Adverse-Effect Level (NOAEL) is the highest exposure
level at which no harmful effects were seen in the organ system studied.
Key number 18 reports a NOAEL of 3 ppm for the respiratory system which was
used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see
footnote "c"). 
(9). LOAEL A Lowest-Observed-Adverse-Effect Level (LOAEL) is the lowest
exposure level used in the study that caused a harmful health effect.
LOAELs have been classified into "Less Serious" and "Serious" effects. 
These distinctions help readers identify the levels of exposure at which
adverse health effects first appear and the gradation of effects with 
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increasing dose. A brief description of the specific end point used to
quantify the adverse effect accompanies the LOAEL. The "Less Serious"
respiratory effect reported in key number 18 (hyperplasia) occurred at a
LOAEL of 10 ppm. 
(10). Reference  The complete reference citation is given in Chapter 8 of the
profile. 
(11). CEL  A Cancer Effect Level (CEL) is the lowest exposure level associated
with the onset of carcinogenesis in experimental or epidemiological
studies. CELs are always considered serious effects. The LSE tables and
figures do not contain NOAELs-for cancer, but the text may report doses
which did not cause a measurable increase in cancer. 
(12). Footnotes  Explanations of abbreviations or reference notes for data in
the LSE tables are found in the footnotes. Footnote "c" indicates the 
NOAEL of 3 ppm in key number 18 was used to derive an MRL of 0.005 ppm. 
LEGEND 
See LSE Figure 2-l 
LSE figures graphically illustrate the data presented in the corresponding LSE
tables. Figures help the reader quickly compare health effects according to
exposure levels for particular exposure duration. 
(13). Exposure Duration The same exposure periods appear as in the LSE table.
In this example, health effects observed within the intermediate and
chronic exposure periods are illustrated. 
(14). Health Effect These are the categories of health effects for which
reliable quantitative data exist. The same health effects appear in the
LSE table. 
(15). Levels of Exposure  Exposure levels for each health effect in the LSE
tables are graphically displayed in the LSE figures. Exposure levels are
reported on the log scale "y" axis. Inhalation exposure is reported in
mg/m3 or ppm and oral exposure is reported in mg/kg/day. 
(16). NOAEL  In this example, 18r NOAEL is the critical end point for which an
intermediate inhalation exposure MRL is based. As you can see from the
LSE figure key, the open-circle symbol indicates a NOAEL for the test
species (rat). The key number 18 corresponds to the entry in the LSE
table. The dashed descending arrow indicates the extrapolation from the
exposure level of 3 ppm (see entry 18 in the Table) to the MRL of 0.005
ppm (see footnote "b" in the LSE table). 
(17). CEL  Key number 38r is one of three studies for which Cancer Effect Levels
(CELs) were derived. The diamond symbol refers to a CEL for the test
species (rat). The number 38 corresponds to the entry in the LSE table. 
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(18). Estimated Upper-Bound Human Cancer Risk Levels  This is the range
associated with the upper-bound for lifetime cancer risk of 1 in 10,000
to 1 in 10,000,000. These risk levels are derived from EPA's Human Health 
Assessment Group's upper-bound estimates of the slope of the cancer dose
response curve at low dose levels (q1*). 
(19). Key to LSE Figure  The Key explains the abbreviations and symbols used in
the figure. 
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Chapter 2 (Section 2.4) 
Relevance to Public Health 
The Relevance to Public Health section provides a health effects summary based
on evaluations of existing toxicological, epidemiological, and toxicokinetic
information. This summary is designed to present interpretive,
weight-of-evidence discussions for human health end points by addressing the
following questions. 
1.	 What effects are known to occur in humans? 
2.	 What effects observed in animals are likely to be of concern to
humans? 
3.	 What exposure conditions are likely to be of concern to humans,
especially around hazardous waste sites? 
The section discusses health effects by end point. Human data are presented
first, then animal data. Both are organized by route of exposure (inhalation,
oral, and dermal) and by duration (acute, intermediate, and chronic). In vitro
data and data from parenteral routes (intramuscular, intravenous, subcutaneous,
etc.) are also considered in this section. If data are located in the
scientific literature, a table of genotoxicity information is included. 
The carcinogenic potential of the profiled substance is qualitatively evaluated,
when appropriate, using existing toxicokinetic, genotoxic, and carcinogenic data.
ATSDR does not currently assess cancer potency or perform cancer risk
assessments. MRLs for noncancer end points if derived, and the end points from
which they were derived are indicated and discussed in the appropriate
section(s). 
Limitations to existing scientific literature that prevent a satisfactory
evaluation of the relevance to public health are identified in the Identification
of Data Needs section. 
Interpretation of Minimal Risk Levels 
Where sufficient toxicologic information was available, MRLs were derived. MRLs
are specific for route (inhalation or oral) and duration (acute, intermediate,
or chronic) of exposure. Ideally, MRLs can be derived from all six exposure
scenarios (e.g., Inhalation - acute, -intermediate, -chronic; Oral - acute, ­
intermediate, - chronic). These MRLs are not meant to support regulatory action,
but to aquaint health professionals with exposure levels at which adverse health
effects are not expected to occur in humans. They should help physicians and
public health officials determine the safety of a community living near a
substance emission, given the concentration of a contaminant in air or the
estimated daily dose received via food or water. MRLs are based largely on
toxicological studies in animals and on reports of human occupational exposure. 
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MRL users should be familiar with the toxicological information on which the
number is based. Section 2.4, "Relevance to Public Health," contains basic 
information known about the substance. Other sections such as 2.6, "Interactions 
with Other Chemicals" and 2.7, "Populations that are Unusually Susceptible"
provide important supplemental information. 
MRL users should also understand the MRL derivation methodology. MRLs are
derived using a modified version of the risk assessment methodology used by the
Environmental Protection Agency (EPA) (Barnes and Dourson, 1988; EPA 1989a) to
derive reference doses (RfDs) for lifetime exposure. 
To derive an MRL, ATSDR generally selects the end point which, in its best
judgement, represents the most sensitive human health effect for a given exposure
route and duration. ATSDR cannot make this judgement or derive an MRL unless
information (quantitative or qualitative) is available for all potential effects
(e.g., systemic, neurological, and developmental). In order to compare NOAELs
and LOAELs for specific end points, all inhalation exposure levels are adjusted
for 24hr exposures and all intermittent exposures for inhalation and oral routes
of intermediate and chronic duration are adjusted for continuous exposure (i.e.,
7 days/week). If the information and reliable quantitative data on the chosen
end point are available, ATSDR derives an MRL using the most sensitive species
(when information from multiple species is available) with the highest NOAEL that
does not exceed any adverse effect levels. The NOAEL is the most suitable end
point for deriving an MRL. When a NOAEL is not available, a Less Serious LOAEL
can be used to derive an MRL, and an uncertainty factor (UF) of 10 is employed.
MRLs are not derived from Serious LOAELs. Additional uncertainty factors of 10
each are used for human variability to protect sensitive subpopulations (people
who are most susceptible to the health effects caused by the substance) and for
interspecies variability (extrapolation from animals to humans), In deriving an
MRL, these individual uncertainty factors are multiplied together. The product
is then divided into the adjusted inhalation concentration or oral dosage
selected from the study. Uncertainty factors used in developing a
substance-specific MRL are provided in the footnotes of the LSE Tables. 




